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SUMMARY 
The tumor microenvironment (TME) is now recognized as an important factor in breast 
cancer progression and is crucial in determining the response to anti-cancer therapies. 
Fibroblasts are one component of the TME that are activated in the early stages of 
oncogenesis and remodel the TME as an early tissue repair response. In the later stages of 
tumor progression, these activated fibroblasts get transformed into cancer associated 
fibroblasts (CAFs) that promote tumor progression. The mechanisms underlying this 
transformation of fibroblasts from normal activated fibroblasts to CAFs remain largely 
unknown. To address this, bone marrow derived mesenchymal stromal cells (MSCs) that 
are known to be a significant source of CAFs were treated with conditioned media of a 
breast cancer cell line, namely, MDA-MB-23, to induce a CAF-like - phenotype. 
Activation of MSCs was confirmed by assessing their contractility and expression of CAF 
markers. Gene expression and secretome analysis was performed to identify differentially 
expressed genes and differentially secreted factors upon activation. Stanniocalcin 1 
(STC1), a CAF-secreted protein implicated in metastasis and therapy resistance, was found 
to be upregulated upon conditioned media treatment. Therefore, the aim of this study was 
to understand the mechanism of STC1 upregulation and its involvement in the activation 
of fibroblasts. STC1 knockdown using RNAi both in conditioned media treated MSCs and 
patient derived activated CAFs showed inhibitory effects on activation status of these cells. 
Moreover, this down-regulation resulted in a decrease in the expression of several proteins 
such as NOTCH3, NOTCH4 and β-catenin suggesting possible mechanisms by which 
STC1 regulates the activation of fibroblasts. Furthermore, the upregulation of STC1 upon 
conditioned media treatment was found to be dependent on RELA and RELB transcription 
factors indicating that NF-κB signaling might be involved in its transcriptional regulation. 
In conclusion, this study demonstrates STC1 as an important factor in the activation of 
CAFs. Investigating the mechanism of the involvement of STC1 in the unabated activation 
of CAFs will enable a deeper understanding of the tumor microenvironment and its role in 
the tumor progression.  
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ZUSAMMENFASSUNG 
Die Tumormikroumgebung (tumor microenvironment, TME) wird heute als ein 
bedeutender Faktor bei der Progression von Brustkrebs betrachtet und spielt eine zentrale 
Rolle beim Ansprechen auf Krebstherapien. Fibroblasten sind einer der Bestandteile der 
TME. Sie werden zu einem frühen Zeitpunkt der Onkogenese aktiviert und formen die 
TME im Rahmen einer Reaktion der Gewebereparatur um. Im Laufe der Tomorprogression 
werden diese aktivierten Fibroblasten zu Krebs-assoziierten Fibroblasten (cancer-
associated fibroblasts, CAFs), die das Voranschreiten der Krankheit zusätzlich 
begünstigen. Die Mechanismen, die die Transformation von normalen, aktivierten 
Fibroblasten zu CAFs begründen, sind bislang größtenteils unbekannt.  
Um diese Mechansimen zu untersuchen wurden mesenchymale Stammzellen 
(mesenchymal stem/stromal cells, MSCs) aus dem Knochenmark, die als bedeutende 
Quelle von CAFs in Patienten gelten, mit konditioniertem Medium einer 
Brustkrebszelllinie, MDA-MB-231, behandelt, um einen CAF-ähnlichen Phänotyp zu 
erzeugen. Die Aktivierung der MSCs wurde bestätigt, indem ihre Kontraktilität und die 
Expression von CAF-Markern bestimmt wurden. Genexpressions- und Sektretom-
Analysen wurden durchgeführt, um nach der Aktivierung differentiell exprimierte Gene 
und differentiell sezernierte Proteine zu identifizieren. 
Stanniocalcin 1 (STC1), ein von CAFs sezerniertes Protein mit Implikationen auf 
Metastasierung und Therapieresistenz, war nach der Behandlung mit konditioniertem 
Medium stärker exprimiert und in größeren Mengen sezerniert.  Aus diesem Grund war 
das Ziel dieser Studie, den Mechanismus der Hochregulation von STC1 sowie die 
Beteiligung dieses Proteins an der Aktivierung von Fibroblasten zu verstehen.  
Knockdown von STC1 mithilfe von RNAi verringerte sowohl bei MSCs, die mit 
konditioniertem Medium behandelt worden waren, als auch bei konstitutiv aktivierten 
CAFs aus Brustkrebspatientinnen den Aktivierungsstatus der Zellen. Weiterhin führte der 
Knockdown zu einer verminderten Expression mehrerer Proteine, wie beispielsweise 
NOTCH3, NOTCH4 und β-Catenin. Hieraus können Hypothesen für potentielle 
Mechanismen abgeleitet werden, die der Regulation der Aktivierung von Fibroblasten 
durch STC1 zugrunde liegen. Darüber hinaus konnte gezeigt werden, dass die 
Hochregulierung von STC1 nach der Behandlung mit konditioniertem Medium von den 
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Transkriptionsfaktoren RELA und RELB abhängig war, was eine Beteiligung von NFκB 
an der transkriptionellen Regulation von STC1 nahelegt. 
Zusammenfassend etabliert diese Studie STC1 als einen bedeutenden Faktor in der 
Aktivierung von CAFs. Die weitere Aufklärung der zugrundeliegenden Mechanismen wird 
zu einem vertieften Verständnis der Tumormikroumgebung und ihrer Rolle in der 
Tumorprogression beitragen. 
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1. INTRODUCTION 
1.1. Breast Cancer 
Breast cancer, the most common cancer type in women, ranks as the second leading cause 
of cancer mortality after lung cancer and represents 14% of all cancer related deaths in 
women worldwide (American Cancer Society, 2018). It is a heterogeneous disease with 
multiple subgroups that differ in their molecular features, response to therapies and 
prognosis which makes the breast cancer diagnosis and treatment a challenging task.  
 
1.1.1. Molecular subtypes 
Using immunohistochemistry techniques, breast cancer traditionally has been classified 
into three major types; hormone receptor positive tumors that express estrogen receptor 
(ER) and/or progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) 
positive tumors and triple negative breast tumors which are negative for the expression of 
ER, PR and HER2 (Carlson et al., 2009). High throughput gene expression profiling and 
hierarchical clustering of breast tumors have further divided these initial three major types 
into several distinct molecular subtypes of breast cancer including luminal A, B, 
HER2enriched, basal, and claudin-low which differentially express ER, PR and HER2 
together with the genes regulated under the control of these receptors (Kittaneh et al., 
2013). Luminal subtypes of breast cancer, namely luminal A and luminal B, have 
expression profiles that are similar to  the luminal epithelial component of the normal breast 
(Perou et al., 2000).  Luminal A subtype is the most common subtype that corresponds to 
around half of the total cases of breast cancer (Fan et al., 2006). Luminal A tumors are ER 
positive with overexpression of ER regulated genes such as LIV1 and CCND1 but they lack 
the expression of ERBB2 receptor and have low levels of expression of proliferation related 
genes (Yersal & Barutca, 2014). They have the best prognosis (Z. Hu et al., 2006) and the 
lowest recurrence rates among all the subtypes (Metzger-Filho et al., 2013). Luminal B 
subtype corresponds to around 20% of all cases of breast cancer (Sorlie et al., 2001). It has 
a similar expression pattern to that of luminal A. However, it has higher variability in the 
expression of ER and higher expression of proliferative genes, e.g., Ki67, that might be 
associated with mutations in TP53 and genomic instability (Alcalá-Corona et al., 2017). 
Compared to luminal A tumors, luminal B ones have poorer prognosis (Haque et al., 2012). 
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The HER2-enriched subtype of breast cancer is characterized by overexpression of the 
ERRBB2 receptor which is mostly accompanied by chromosomal level amplification of 
the gene locus (Burstein, 2005). 40-80% of these tumors have mutations in TP53 and they 
have poorer prognosis and higher relapse risk compared to the luminal subtypes (Yang et 
al., 2011). Tumors of the basal subtype of breast cancer have a gene expression profile that 
is similar to the basal mammary epithelium (Alcalá-Corona et al., 2017) with high 
expression of basal markers such as keratin 5, 6, 14, and 17 and EGFR (Dai et al., 2015). 
20% of all breast cancer cases corresponds to this subtype and the majority of triple 
negative tumors that are lacking expression of ER, PR and HER2 belong to the basal 
subtype (Alcalá-Corona et al., 2017). Triple negative tumors generally have TP53 mutation 
(O’Brien et al., 2010), low BRCA1 expression (Abd El-Rehim et al., 2005) and they are 
associated with higher genetic instability. Therefore, they are the most aggressive tumors 
with poorest 5-year survival rates (Alcalá-Corona et al., 2017). Another subtype that also 
has triple negative tumors is claudin-low which has low expression of genes involved in 
tight junctions and cell-cell adhesions including claudin 3, 4 and 7, occluding and E-
cadherin. Like the other triple negative tumors, claudin low tumors also have poor clinical 
outcome (Yersal & Barutca, 2014).  
 
1.1.2. Therapy 
Various therapeutic approaches can be used for the management of breast cancer according 
to the stage and molecular subtype of the tumor. Surgery and radiotherapy are still the gold 
standards in the treatment of breast cancer. In some cases, radiotherapy or chemotherapy 
can be used as a neoadjuvant therapy prior to surgery aimed to shrink the tumor. 
Pathological and molecular classification come into the play in the planning of adjuvant 
therapy after the surgery to increase the chance of cure by eradicating micro-metastatic 
disease (Yeo et al., 2014). 
Endocrine therapy is the main treatment option for hormone receptor positive luminal 
tumors. It works by blocking the effects of hormones, mostly of estrogen, that are involved 
in disease progression. Tamoxifen is a selective estrogen receptor modulator and is the 
most commonly used drug for the luminal subtype. It is an estrogen analog thereby it blocks 
the binding of estrogen to its receptor and inhibits proliferative activities of estrogen. 
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Adjuvant usage of tamoxifen for 5 years after surgery has been shown to reduce the risk of 
relapse by 41% and death from breast cancer by 31% making it the standard of care for 
premenopausal women (Yeo et al., 2014). Another class of endocrine therapeutic drugs is 
aromatase inhibitors such as letrozole, anastrozole and exemestane that inhibit conversion 
of androgen to estrogen thus leading to estrogen depletion. Aromatase inhibitors have been 
demonstrated to be superior to tamoxifen for postmenopausal women (Yeo et al., 2014). 
Some patients of luminal breast cancer might have intrinsic or acquired resistance to 
endocrine therapy. Therefore, additional therapies have been developed to combine with 
different endocrine therapies. Cyclin-dependent kinase 4 and 6 inhibitors such as 
palbociclib, ribociclib and abemaciclib, for example, have been used in combination with 
hormonal therapy in patients with metastatic luminal tumors that lack HER2 expression 
(H. Xu et al., 2017). Other possible therapeutic options include PI3K inhibitors, mTOR 
inhibitors, histone deacetylase inhibitors and steroid sulfatase inhibitors (Tong et al., 2018). 
For patients with HER2 overexpressing tumors, the main therapeutic approach is to utilize 
molecular agents targeting ERBB2 receptor, alone or in combination with chemotherapy. 
These molecular agents include trastuzumab and pertuzumab, directly targeting HER2, 
ado-trastuzumab, an antibody-cytotoxic agent conjugate and lapatinib, a dual tyrosine 
kinase inhibitor (Tong et al., 2018). It has been shown that trastuzumab administrated in 
combination with chemotherapy significantly improves overall survival of HER2 
overexpressing breast cancer (Slamon et al., 2001). Lapatinib is used together with 
chemotherapy in the patients that do not benefit from trastuzumab therapy (Geyer et al., 
2006). 
Lack of expression of hormonal receptors and HER2 make triple negative breast cancer 
(TNBC) difficult to treat and despite the recent advances in targeted therapy field, 
chemotherapy still remains as the standard treatment for this type of cancer. TNBC has the 
highest complete response rate to chemotherapy compared to all the other subtypes 
however, recurrence and metastasis rates are also higher (Liedtke et al., 2008). Therefore, 
new novel therapy strategies are required for the treatment of TNBC. Most of the TNBC 
have deficiency in their homologous repair mechanism mostly due to BRCA mutations. 
Therefore, Poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to have 
promising clinical outcomes in patients with mutations in BRCA1/BRCA2 and/or other 
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genes involved in DNA damage response (Bryant et al., 2005). Clinical trials 
administrating anti-angiogenic agents like bevacizumab in combination with 
chemotherapy showed higher response rate to therapy in metastatic TNBC (Robert et al., 
2011). Due to its promising outcomes in many different cancer types, Pembrolizumab, a 
monoclonal antibody against PD-1, has been subjected to several clinical trials also in 
TNCB. It has been demonstrated that Pembrolizumab has durable antitumor activity in 
some patients with heavily pretreated metastatic TNBC (Adams et al., 2017) and its effect 
is independent of PD-L1 expression (Nanda et al., 2016).  
 
1.1.3. Role of the tumor microenvironment in breast tumorigenesis 
There have been recent advances in the detection, therapy and understanding of the 
molecular basis of breast cancer. However, the recurrence of the disease and resistance to 
therapeutic drugs are still some of the major clinical problems. While the main focus of 
breast cancer research had been on the investigation of the molecular events in breast 
epithelial cells that lead to the formation of malignant tumors for long, the tumor 
microenvironment is now recognized as an important player in tumor development because 
of the structural, cellular, functional, genetic, and epigenetic changes in the tumor stroma 
that can influence breast cancer progression (Artacho-Cordón et al., 2012). 
The normal breast duct is composed of luminal epithelial and myoepithelial cells 
surrounded by extracellular matrix (ECM), endothelial cells, fibroblasts, immune cells, 
adipocytes and other stromal cells. The stromal compartment in the breast 
microenvironment has been shown to affect the terminal differentiation of epithelia and be 
involved in the mammary duct morphogenesis via affecting the epithelial phenotype 
(Maller et al., 2010). In addition to its influence on the normal mammary development, the 
microenvironment has been also reported to regulate the growth and differentiation state 
of breast cancer cells via different mechanisms (Allinen et al., 2004). 
Cancer cells evolve together with their microenvironment. As the tumor progresses and 
gains new characteristics, the abundance, histologic organization and phenotypic properties 
of the stromal cells also change and this enables the transformation of the tumor from 
primary to invasive and to metastatic tumors (Hanahan & Weinberg, 2011). Therefore, it 
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is crucial to identify each cell type in the tumor microenvironment that can have different 
functions in the different stages of tumor development (Figure 1). 
 
 
Figure 1 Role of the tumor stroma in cancer progression Stromal cells can be involved in each 
step of tumor progression. Tumor associated macrophages, cancer associated fibroblasts and 
pericytes contribute to epithelial-mesenchymal transition of the primary tumor cells and induce the 
transformation into a more invasive phenotype. With the help of tumor associated macrophages 
tumor cells can intravasate into the blood circulation. Once in the blood circulation, platelets escort 
tumor cells to the site of extravasation and help them to exit the circulation to enter secondary 
tissues. At the secondary sites, myeloid derived suppressor cells and natural killer cells create an 
immunosuppressive microenvironment and contribute to the re-colonization of cancer cells (image 
taken from Quail & Joyce, 2013).  
 
The first step in breast cancer development is the transformation of a single cell due to the 
accumulation of genetic and epigenetic changes. After epithelial hyperproliferation, the 
tumor progresses to in situ, invasive and metastatic carcinomas (Polyak, 2007). In a gene 
profiling study comparing normal epithelial cells with non-invasive primary tumors, it has 
been found that in addition to the genes regulating cell growth and differentiation, a 
significant fraction of secreted proteins is differentially expressed. This suggests the 
activation of aberrant autocrine and paracrine regulatory loops that would lead to the 
identified alterations in the tumor microenvironment (Allinen et al., 2004). In non-invasive 
breast carcinoma stage, it has been observed that there is an increase in the number of 
infiltrated leukocytes and fibroblast. These secrete growth factors, cytokines, chemokines, 
Dissertation   Neşe Erdem 
 
 
24 
and matrix metalloproteinases (MMPs) thus jointly promoting tumor growth and 
progression (Place et al., 2011). The transition from non-invasive to invasive and metastatic 
carcinomas is also accompanied by changes in the tumor microenvironment. Several genes 
associated with the components of the ECM such as MMPs have been reported to be 
differentially expressed between non-invasive and invasive or metastatic tumors (Schäfer 
& Werner, 2008). The ECM is one of the components of tissues together with cells and 
vascular space and it is composed of approximately 300 proteins. The ECM is one of the 
major components of the tumor microenvironment and it is involved in cancer development 
and progression. Tumors and stromal cells can remodel their surrounding ECM by 
increasing deposition and crosslink of ECM proteins that can facilitate cancer cell 
proliferation, migration and invasion (Xiong & Xu, 2016). For example, it has been shown 
that crosslinked and oriented collagen in breast cancer correlates with poor survival 
(Conklin et al., 2011).  
One of the hallmarks of cancer is tumor promoting inflammation (Hanahan & Weinberg, 
2011). Immune cells of both adaptive and innate immunity infiltrate the tumor site and 
create an inflammatory tumor microenvironment. Every neoplastic lesion contains immune 
cells at different densities because of the attempt of the immune system to clear tumor cells 
(Pagès et al., 2010). However, tumors can evade immune responses and even make use of 
the presence of the immune cells as it has been shown repeatedly that chronic inflammation 
promotes tumor growth and progression (Gonda et al., 2009). Tumor infiltrating 
lymphocytes (TILs), mainly consisting of T cells, are among the important players of the 
breast tumor microenvironment. It has been demonstrated that different breast cancer 
subtypes have different quantities of infiltrating T cells (Miyan et al., 2016) with TNBC 
having the highest number of TILs in their tumor microenvironment (Stanton & Disis, 
2016). The population of infiltrating T cells consists of CD8+ cytotoxic T cells, CD4+ 
helper T cells and CD4+ regulatory T cells (Tregs). CD8+ cytotoxic T cells are the main T 
cell type with anti-tumor immunity properties, therefore, the number of infiltrating CD8+ 
T cells reversely correlates with ER and PR expression (Mahmoud et al., 2011). In the early 
phases of tumor development, T cells act as anti-tumorigenic entities. However, as the 
tumor progress, they differentiate into Tregs with tumor promoting properties. It has been 
shown that TNBC has higher numbers of Tregs compared to the other subtypes (Stanton & 
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Disis, 2016).  Tumor-associated macrophages (TAMs) are another major factor in the 
tumor stroma of breast cancer. They are recruited to the tumor site via CCL2 that is 
produced by the tumor and get activated via CSF-1 which is also secreted by breast cancer 
cells. As a result they secrete EGF which promotes cancer growth (Qian et al., 2011). 
TAMs have also been reported to produce significant amounts of MMPs which are crucial 
factors in the degradation of the ECM thus facilitating local invasion of breast cancer cells 
(Qian & Pollard, 2010). Another component of the tumor microenvironment is the tumor-
associated vasculature, comprised of endothelial cells. Under the influence of the tumor 
microenvironment, they can undergo an angiogenic switch, which is important for the 
tumor to exceed a certain size and metastasize to secondary organs. In addition to immune 
cells and endothelial cells, there is another cell type in the tumor microenvironment, 
namely fibroblasts that are discussed in detail in the following chapter.  
 
1.2. Fibroblasts  
Fibroblasts are first described as elongated cells in connective tissue that synthesize 
collagen (Virchow, 1858). Today, it is known that they are the most common cell type in 
connective tissue in animals and can be defined as non-epithelial and non-immune cells 
that produce structural proteins of the extracellular matrix. In normal tissues, they present 
as single cells in a quiescent or resting state and are located in the interstitial space or near 
capillaries (Kalluri, 2016).  
Fibroblasts are mesenchymal cells that are derived from embryonic mesoderm tissue. They 
are found in every tissue in the body and depending on their anatomical site, their 
morphologies might differ. Fibroblasts located in different sites of body, have been also 
shown to have different gene expression patterns (Sorrell & Caplan, 2009) that might 
suggest that they take up their relative position in the body during development. However, 
the influences of different microenvironments on fibroblast characteristics cannot be 
excluded (Tschumperlin, 2013).  
The main role of fibroblasts is the production and secretion of components of the ECM. 
They produce structural extracellular protein fibers that form an interconnecting 
meshwork. These structures can form lamina separating different cell types or interstitial 
regions connecting cells with common features. Different tissues require different type of 
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structural ECM proteins, depending on their biological functions. For example, tissues that 
are different in morphology in terms of degree of flexibility vs. rigidity, have different 
expression levels of collagen and elastin proteins thus providing rigidity or elasticity, 
respectively. Another protein type that is produced by fibroblasts is adhesive ECM proteins 
such as fibronectin and laminin that are important to connect cells with the ECM. Both are 
involved in interaction with integrin receptors. Fibroblasts also produce the ground 
substance of the ECM by secreting proteoglycans. The latter form a cell free medium that 
is essential for cell migration of immune cells, fibroblasts and endothelial cells. In addition 
to providing a surface for cell migration, proteoglycans that are post-translationally 
modified by the addition of glycosaminoglycans, are also involved in cell signaling 
(Kendall & Feghali-Bostwick, 2014). In addition to their main role in extracellular matrix 
production and maintenance, fibroblasts are also involved in physiological processes such 
as inflammation and wound healing. 
 
1.2.1. Wound healing  
In case of an injury, integrity and homeostasis has to be restored immediately. Wound 
healing is a multistep, complex biological process in which various pathways need to be 
activated. Three overlapping phases of wound healing are inflammation, new tissue 
formation or proliferation and remodeling (Gonzalez et al., 2016).  
Inflammation occurs directly after tissue damage. Coagulation cascade, inflammatory 
pathways and immune system are activated at this stage to prevent ongoing blood and fluid 
losses, to remove dead tissues and to prevent infection (Gurtner et al., 2008) . Aggregation 
of thrombocytes followed by formation of fibrin matrix creates a scaffold for infiltrating 
cells. First neutrophils infiltrate the lesion that activated by pro-inflammatory cytokines 
such as IL-1, TNF- and IFN-. These cytokines induce the expression of several 
adhesion molecules that are LFA-1, MAC-1, gp150/95 and CD11d/CD18 that are involved 
in extravasation (Eming et al., 2007). Upon recruitment to the wound, neutrophils are 
involved in several processes such as killing invading microorganisms, resolution of fibrin 
clot, promoting angiogenesis and re-epithelization (Shaw & Martin, 2009). The second 
inflammatory cell type that is recruited to the injury side is monocytes that differentiate 
into macrophages. Macrophages clear up matrix, cell debris and also neutrophils. They are 
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also important for recruiting other inflammatory cells by producing chemotactic factors 
(Eming et al., 2007).  
In the second phase of wound healing that is proliferation, the aim is the closure of wound 
gap and replenishment of lost tissue by contraction, fibroplasia, angiogenesis and re-
epithelialization (Gonzalez et al., 2016). At this stage, fibroblasts, recruited to the wound 
via chemokines secreted by macrophages. They contribute to the formation of new stroma 
(granulation tissue) that replaces the fibrin clot by involving in synthesizing, bundling and 
alignment of type III collagen fibers that are the main components of connective tissue scar 
(Boris Hinz, 2007). Moreover, activated fibroblasts (see section 1.2.2.) accumulated on the 
wound borders, contract and bring the edges of the wound toward the center. Contraction 
of activated fibroblasts can be calcium‐calmodulin‐myosin light chain kinase or Rho-
ROCK-myosin light chain phosphatase dependent (Bochaton-Piallat et al., 2016). Large 
focal adhesion complexes transmit the contractile forces generated by fibroblast to ECM 
that results in pulling and compacting the surrounding matrix into scar tissue (Carthy, 
2018a).  
The last phase of wound healing is remodeling. The main aim of this phase is to obtain 
maximum tensile strength of the wound by reorganization, degradation and  re-synthesis 
of the ECM (Gonzalez et al., 2016). Type III collagen is replaced with type I collagen that 
has more tensile strength. There is a reduction in the number of new blood vessels and 
blood flow. Moreover, the inflammatory response to injury resolves and neutrophils are 
cleared up (Landén et al., 2016).   
 
1.2.2. Activation of fibroblasts 
Activated fibroblasts were first described in the context of wound healing as cells that that 
might be involved in wound contraction (Gabbiani et al., 1971). These cells were later 
called myofibroblasts because of both their resemblance to smooth muscle cells and their 
alpha-smooth muscle actin (SMA) expression (Gabbiani et al., 1978; Skalli et al., 1986). 
They take part in proliferation phase of wound healing (see section 1.2.1.) and once the 
wound closes, they disappear through apoptosis (Desmoulière et al., 1995). Activated 
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fibroblasts are also present in fibrotic diseases such as scleroderma, liver, kidney and lung 
fibrosis and in repairing heart after myocardial infarction (Bochaton-Piallat et al., 2016).  
To better understand what an activated fibroblast is, it is crucial to define the properties of 
a quiescent fibroblast. Adult quiescent fibroblasts are found in the interstitial stromal areas 
between layers of functional parenchyma and detected as thin elongated cells that have 
extensions and spindle-like shape. Although there is no absolute marker for quiescent 
fibroblasts, fibroblast-specific protein 1 (FSP1) has been considered as the closest one 
(Strutz et al., 1995; Kalluri, 2016). They are defined as quiescent because of their ability 
to respond to stimuli to become activated. Apart from their activation ability, other possible 
functions of quiescent fibroblasts are still mainly unknown. Isolating fibroblasts from most 
tissues relays on the fact that upon digestion of the tissue, fibroblasts are the only 
population of cells that can easily adhere and be cultured on plastic surfaces. There is a 
lack of knowledge on the molecular properties of quiescent fibroblasts because upon 
isolation, they lose their quiescent state and become activated due to artificial culture 
conditions. Moreover, embryonic and developing tissues do not have fibroblasts but 
probably active mesenchymal cells of which most undergo apoptosis and a few revert to a 
quiescent state once development is completed. Therefore, all the knowledge of fibroblasts 
come from their activated phenotype (Kalluri, 2016).  
Activated fibroblasts have been shown to be highly heterogeneous with distinct gene 
expression patterns depending on the tissue that they are isolated from (H. Y. Chang et al., 
2002). When there is a stimulus that can be an injury, stress or inflammation, quiescent 
fibroblasts can be reversibly activated (Figure 2). These activated fibroblasts start 
expressing makers such SMA and vimentin. As a result of cytoskeletal rearrangements, 
their morphology changes from spindle to stellate shape. They gain contractile and 
migratory phenotype that is required in wound healing process. They start proliferating and 
contribute to ECM remodeling by secreting various factors. When the wound healing is 
completed, this activation could be reverted by reprogramming or activated fibroblasts 
could be cleared up by apoptosis. When there is persisting and unabated stimuli as in the 
case of fibrosis or cancer, activated fibroblasts gain more secretory phenotypes, specialized 
ECM remodeling ability, robust autocrine activation and immunomodulatory signaling 
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functions (Kalluri, 2016). This last step might be irreversible through epigenetic 
regulations (Zeisberg & Zeisberg, 2013 ; Bechtel et al., 2010). 
 
 
Figure 2 Multi-step activation of fibroblasts (Kalluri, 2016) 
 
How this activation is regulated at molecular level is the subject of ongoing research. The 
most well-known inducer of fibroblast activation is TGF (Carthy, 2018a). TGF  is 
secreted by the cells in its inactive form that needs to be activated in the ECM by proteolytic 
cleavage. Active TGF is free to bind to its receptor, TGFR2. Upon ligand binding 
TGFR2 phosphorylates TGFR1 that induces phosphorylation of receptor activated Smad 
proteins which in turn translocate to the nucleus. In the nucleus, Smad proteins recognize 
specific Smad binding elements (SBE) in the enhancer or promoter regions of TGF 
pathway target genes. TGF can also activate non-Smad pathways including MAPK 
pathway, Rho-like GTPases and PI3K signaling (Carthy, 2018b). Involvement of TGF in 
the activation of fibroblasts has been shown for the first time in context of fibrosis using 
Smad3 knockout mouse models. Mice lacking Smad3 have been found to be protected 
against fibrosis in different disease models (Sato et al., 2003; Flanders et al., 2002). Later 
on, TGF signaling has been also associated with αSMA expression due to presence of 
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SBE in the proximal promoter region of ACTA2 gene (B. Hu et al., 2003). Wnt signaling 
is also involved in the activation of fibroblasts via crosstalk with TGF pathway. Upon 
activation of Wnt signaling, the effector of Wnt signaling pathway, namely, β-Catenin, 
translocates to nucleus and via formation of transcriptional complexes with TCF/LEF 
family transcription factors, it induces transcription of Wnt target genes (Clevers & Nusse, 
2012). It has been demonstrated that β-catenin, that is activated as a result of TGFβ 
signaling, can form a complex with pSmad3 and the histone acetyltransferase CREB-bind 
protein (CBP) at the upstream SBE in the αSMA promoter (Zhou et al., 2012). In another 
study, it has been shown that induction of Wnt signaling by activated TGFβ pathway is 
required for TGFβ mediated fibrosis (Akhmetshina et al., 2012). Moreover, cancer cell 
derived Wnt7a has been reported to activate fibroblasts via TGFβ dependent manner 
(Avgustinova et al., 2016). Another pathway that is found to be associated with the 
activated fibroblasts is NF-κB pathway. As a transcription factor NF-κB is expressed in 
nearly all cell types and regulates the expression of a wide variety of genes with different 
functions. There are five members of this transcription factor family that share structural 
features and form homo- or heterodimers (Ghosh et al., 1998). When the dimers are in their 
inactive form, they are bound to the inhibitory molecules that belong to the IκB protein 
family. The activation of the pathway generally leads to the proteasomal degradation of the 
IκB molecules, which results in release and subsequent transportation of NF-κB to the 
nucleus where it acts as a transcription factor (Napetschnig & Wu, 2013). It is not clear if 
NF-κB pathway is required for the fibroblast activation. However, it is known that 
inflammatory features associated with activated fibroblasts are dependent on NF-κB 
signaling (Erez et al., 2010).  
Activated fibroblasts are predominant stromal cells of human tumors. In the context of 
cancer, they are called cancer associated fibroblasts (CAFs) that are discussed in the next 
chapter. 
 
1.2.3. Cancer Associated Fibroblasts 
The term, cancer associated fibroblast, is often used to define a complex population of 
dynamically heterogeneous mesenchymal cells found in stroma of solid tumors (LeBleu & 
Kalluri, 2018). In tissue sections of various tumors, CAFs can be identified based on their 
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spindle shape and elongated cytoplasmic processes (Kalluri, 2016). In addition to their 
different morphology, another way to distinguish them from other cells types in the tumor 
is using an exclusion criterion that is lack of expression of endothelial, epithelial and 
immune cell markers. 
Compared to not activated quiescent fibroblasts, CAFs have enhanced proliferation and 
biosynthetic activities such as production of components of ECM, enzymes that are 
involved in ECM remodeling, growth factors and cytokines (LeBleu & Kalluri, 2018). 
Therefore, CAFs are important components of tumor progression and contribute to wide 
range of fibrotic stromal programs of many different tumors (Kalluri, 2016). 
 
1.2.3.1. Origin and heterogeneity  
The origin of CAFs is still an open research question mainly due to their heterogeneity and 
lack of specific markers. However, it has been observed that a significant proportion of 
CAFs are likely derived from cells that have a mesoderm origin  (Madar et al., 2013). When 
a solid tumor arises, cancer cells start forming a neoplastic lesion that develops within the 
tumor microenvironment of the epithelium (Kalluri, 2016). Even at this stage, that is known 
as carcinoma in situ, tumor has a reactive fibrotic microenvironment meaning that 
quiescent fibroblasts residing in the host tissue starts expanding due to the developing 
neoplasm (Ronnov-Jessen et al., 1996).  In addition to residence fibroblasts that are found 
in the organ that cancer starts growing from, CAFs can be also recruited to the tumor side 
from a distant source such as bone marrow (Shiga et al., 2015) (Please see Chapter 1.3.). 
Trans-differentiation of pericytes, endothelial-to-mesenchymal and epithelial-to-
mesenchymal transition programs have been also shown to generate CAF like cells (LeBleu 
& Kalluri, 2018). Growth factors such as TGF, PDGF and FGF2 secreted by cancer cells 
and infiltrating immune cells mediate recruitment of stromal fibroblasts to the tumor. TGF 
that stimulates local CAF proliferation and invasion is the major cytokine in the tumor 
microenvironment for the activation and recruitment of CAFs (Elenbaas & Weinberg, 
2001). Although in theory, origin of CAFs can be determined by lineage tracing studies 
using tumor bearing mice, lack of specific markers for CAFs makes this difficult (LeBleu 
& Kalluri, 2018). There are certain markers whose expressions are associated with CAFs 
but most of these are also expressed by other cell types (Table 1). For example, the most 
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known activated fibroblast or myofibroblast marker is SMA. However, its expression 
might be different in different CAF populations. It has been shown that CAFs that are 
isolated from breast cancer patients have bimodal distribution of ACTA2 expression that 
does not correlate with their activation status (Busch et al., 2017). This indicates that CAFs 
that are coming from the same tumor have different levels of ACTA2 expression that is 
either high or low. 
It was speculated by LeBleu and Kalluri that fibroblasts are activated in the early stages of 
oncogenesis and become CAFs that in turn remodel the tumor microenvironment as a tissue 
repair response and exert antitumor functions. However, as tumor grows, cancer cells use 
CAF secreted factors to facilitate their own survival and proliferation, changing CAFs 
gradually from tumor suppressing to tumor promoting. The mechanisms underlying this 
transformation of fibroblasts from normal activated fibroblasts to CAFs remain largely 
unknown. In different tumor types, these changes can be different due to different 
background of residence fibroblasts. Even, in the same tumor type, CAFs can have distinct 
paracrine actions because of different sources of CAFs within the same tumor. All these 
factors contribute to create both inter and intra-tumor heterogeneity in CAF populations 
(LeBleu & Kalluri, 2018) 
 
Table 1. Different CAF markers and their biological function (modified from LeBleu & Kalluri, 
2018) 
CAF markers Biological functions 
Collagen I, Collagen II, fibronectin, tenascin C, periostin ECM components 
LOX, LOXL1, MMPs, TIMPs 
 
 
 
 
Remodeling enzymes 
TGF, VEGFs, PDGFs, EGF, FGFs, PGE2, CTGF, SDF-1, WNTs 
 
Growth factors and cytokines 
PDGFR/, VCAM1, DDR2, TGFRI/II, EGFR, FGFRs, BMPRI, 
BMPRII, podoplanin, FAP and decreased expression of CAV1 
Receptors and other  
membrane-bound proteins 
Desmin, vimentin, SMA, FSP1 Cytoskeleton components  
and other cytoplasmic proteins 
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1.2.3.2. Roles of CAFs in tumor progression 
There have been publications showing both tumor promoting and tumor restraining 
properties of CAFs that will be discussed in the following chapters. 
 
Tumor promoting functions of CAFs 
Early co-culture studies of CAFs and cancer cells have shown that CAFs contribute to 
tumorigenesis. For example, when SV40 transformed prostate epithelial cell were co-
injected together with normal fibroblasts or CAFs into mice, only CAF co-injected cells   
formed tumors (Olumi et al., 1999). In another study, it has been shown that HSF1 
upregulation in CAFs, support malignancy in breast cancer tumors (Scherz-Shouval et al., 
2014).  
ECM remodeling is one way of CAFs to promote tumor progression. For example, MMP3 
that is produced by activated fibroblasts in breast tumors has been shown to promote 
invasiveness of cancer cells by stimulating epithelial to mesenchymal transition via 
cleaving E-cadherin (Lochter et al., 1997).  In another study, it has been shown that ECM 
remodeling by periostin secreted by fibroblast is important step for preserving cancer stem 
cell niche (Malanchi et al., 2012). Also, CAFs that lack expression of Timp gene, has been 
shown to produce exosomes enriched in ECM proteins and the metalloproteinase 
ADAM10 that cause increase cancer cell motility, metabolic reprogramming and induction 
of cancer stem cell features (Shimoda et al., 2014).  
CAFs also contribute to tumor angiogenesis. In a breast cancer model, xenograft breast 
tumors that were co-injected with CAFs showed increased tumor growth compared to the 
xenografts that were co-injected with normal mammary fibroblasts as a result of enhanced 
angiogenesis by CAF derived CXCL12 (Orimo et al., 2005). In another study that 
unraveled the CAF involvement in angiogenesis in lung carcinoma, it has been shown that 
PDGFA producing tumor cells recruit VEGF producing fibroblasts to the tumor 
microenvironment (Tejada et al., 2006). 
CAFs are also important in secondary tumor growth at the metastatic site. CAFs, in the 
primary tumor, enhances metastasis by secreting potent growth factors and cytokines to 
promote growth and invasiveness of the cancer cells at a distant site (Kalluri, 2016). For 
example, PDGFC and VEGFA that are produced by stromal cells in breast cancer are key 
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for metastatic colonization to the lung (O’Connell et al., 2011). In colorectal cancer, 
stanniocalcin secreted by PDGF-stimulated CAFs, is an important factor for intravasation 
and metastasis (Peña et al., 2013).  
Another important characteristic of CAFs in the tumor microenvironment is their 
immunomodulatory functions. The secretome of CAFs can dynamically evolve during 
tumor progression and affect tumor immunity differently at different stages of tumor 
development (Kalluri, 2016). According to the results of many studies investigating the 
role of CAFs in the regulation of immune system, CAFs have mainly immunosuppressive 
functions. However, it is worth to mention at this point, it has been also considered that 
these observations may be context dependent because most of the studies in this area are 
based largely on in vitro measurements or in vivo experiments using CAFs cultured in vitro 
(Kalluri, 2016). For example, CAFs that have active NF-kappaB signaling has been shown 
to mediate tumor enhancing inflammation by promoting macrophage recruitment, 
neovascularization and tumor growth that was  (Erez et al., 2010). In another study in breast 
cancer, CAFs have been demonstrated to be an important factor involved immune 
polarization in cancer progression by promoting immune suppressive tumor 
microenvironment via recruitment of tumor-associated macrophages, myeloid derived 
suppressor cells and regulator T cells (Liao et al., 2009). In addition to secreting factors 
such as IL-6, IL-4, IL-8, IL-10, TNF, TGFβ, CCL2, CCL5, CXCL9, CXCL10, SDF1, 
PGE2, NO, HGF and HLAG that are involved directly in immunosuppressive functions of 
CAFs, they can also affect immune response indirectly via acquisition of adhesion 
molecules such as ICAM1 that has been shown to provide a docking side for immune cells 
causing their activation, repression and polarization (Kalluri, 2016). 
CAFs are also involved in metabolic regulation of the tumor microenvironment. Factors 
that cause activation of fibroblasts such as TGFβ, PDGF, HIF and ROS mediated 
suppression of CAV1 also promote metabolic shifts in fibroblasts resulting in cells that rely 
on aerobic glycolysis similar to highly proliferating cancer cells (Guido et al., 2012) In 
addition to relying on aerobic glycolysis, CAFs also acquire increased catabolic activity 
and autophagy (Martinez-Outschoorn et al., 2014; Chaudhri et al., 2013). Moreover, it has 
been reported that CAFs produce increased levels of ketone bodies, fatty acids and 
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glutamine and supply anabolic cancer cells with fuel sources for mitochondrial respiration 
(Martinez-Outschoorn et al., 2014; Pavlides et al., 2009).  
Another aspect of tumor progression that CAFs get involved in is drug resistance. It has 
been known for a long time now that organ specific microenvironments play an important 
role in therapy response and resistance (Fidler et al., 1994). In breast cancer, it has been 
shown that a stoma-related gene signature is associated with chemo-resistance and may be 
used to predict the response to chemotherapy in the neoadjuvant setting (Farmer et al., 
2009). In another study, in Her2+ breast cancer, CAF produced HGF has been identified 
as an essential factor in resistance to lapatinib (Watson et al., 2018). Also in non-small cell 
lung cancer, HGF that is secreted by CAFs has been shown to contribute to resistance to 
EGFR tyrosine kinase inhibitors (Yano et al., 2011). In addition to direct effects of CAFs 
on drug response, they can also have indirect effects. CAFs have been shown to increase 
intra-tumoral interstitial fluid pressure thereby contributing to drug resistance by inhibiting 
drug uptake (Heldin et al., 2004).  
 
Tumor restraining functions of CAFs 
While tumor promoting effects of CAFs are generally based on secretion of pro-survival 
factors, their antitumorigenic roles are mostly associated with their functions as regulators 
of antitumor immunity (Kalluri, 2016). The studies, that try to target CAFs in the tumor 
microenvironment because of abundant literature about their tumor promoting functions, 
have been demonstrated the heterogeneity of CAFs and also showed  possible 
antitumorigenic functions (LeBleu & Kalluri, 2018). For instance, in an in vivo setup of 
pancreatic cancer, the depletion of SMA expressing CAFs, using genetically engineered 
mouse models, has resulted in more invasive tumors with increased proportions of 
regulatory T cells (Ozdemir et al., 2014). In another study in pancreatic cancer, the deletion 
of SHH gene from cancer cells has caused reduced stromal content but increased tumor 
aggressiveness (Rhim et al., 2014). Moreover, the secretome of CAFs might also have 
antitumor functions. For example, IL-10, TGFβs, IFNγ and IL-6 are involved in the 
recruitment and polarization of macrophages, NK cells and T cells that contributes to an 
immune control of cancer cells. All in all, it might be speculated that the net effect of CAFs 
on tumor progression might be bimodal mainly due to their heterogeneity  (LeBleu & 
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Kalluri, 2018). Therefore, it is necessary to understand functions of different populations 
of CAFs that have differential gene expression and their different effects on tumor 
progression. 
 
1.3. Mesenchymal Stromal/Stem Cells 
1.3.1. Discovery, origin and plasticity  
Adult stem cells which can be isolated from several tissues in the human body have a long-
term self-renewal ability and they can give rise to more differentiated downstream cell 
lineages (Hsu & Fuchs, 2012). Mesenchymal stem cells (MSCs) were discovered in 1968 
and initially described as bone-marrow-derived stromal cells that can form adherent 
fibroblast-like populations and differentiate into the mesenchymal cell lineages including 
adipocytes, chondrocytes and osteoblasts (Friedenstein et al., 1968). Although, their stem 
cell properties have still not been fully demonstrated in vivo (Ankrum et al., 2014), they 
were named as MSCs because of their in vitro multilineage differentiation potential and 
self-renewal capacity (A I Caplan, 1991). However, with in vivo heterotopic bone 
formation assays, single cell clones derived from only a minor subset of this population has 
been shown to have the potential to generate a miniature bone organ with bone tissue itself, 
cartilage, adipocytes, fibroblasts and hematopoiesis supporting stroma (Friedenstein et al., 
1968) and have the ability to self-renew (Sacchetti et al., 2007). Therefore, it is now 
accepted that initially described mesenchymal ´stem´ cell population, which includes all 
the nonhematopoietic stromal cells in bone marrow, is a heterogeneous population and 
consists of stromal cells and stem cells that could generate skeletal lineages (bone, 
cartilage, adipocyte, hematopoiesis stroma). Not only stemness properties of these cells but 
also the extent of their multi-lineage potential has been a controversial topic. The reasoning 
behind naming these cells as mesenchymal stem cell was based on the hypothesis that in 
addition to their differentiation ability to the skeletal lineages, postnatal MSCs could also 
generate other mesenchymal tissues including skeletal muscle, myocardium, smooth 
muscle and tendon (Caplan, 2005). However, the differentiation ability to the latter is 
highly controversial and still not proven by proper in vivo experiments (Bianco et al., 
2008). Therefore, some scientists referred them as skeletal stem cells to emphasize their in 
vivo proven differentiation potential into skeletal lineages (Bianco et al., 2013). There have 
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been different reports showing that the subpopulation of bone marrow stromal cells with 
real stem cell properties is a very small fraction of all nucleated cells in bone marrow and 
different studies came up with different markers to identify these cells (Table 2).  
 
Table 2. Human and mouse bone marrow mesenchymal stem cell markers tested in vivo 
(modified from Frenette et al., 2013) 
 Cell phenotype 
Mouse 
Nestin+ CD45- CD31- (later identified as CD51+ PDGFRa + CD45- Ter119- CD31-) 
CD51+ CD105+ CD90- CD45- Ter119- 
PDGFRa+ Sca-1+ CD45- Ter119- 
Human 
CD146+ CD45- 
STRO-1bright CD146+ 
STRO-1bright CD106+ 
SSEA4+ 
CD146+/- CD271+ Lin-CD45- 
 
After their discovery in the bone marrow, heterogeneous MSC populations have been also 
identified in other tissue types such as adipose tissue, liver, placenta, umbilical cord blood 
and amniotic fluid. Because of their heterogeneity, a set of standards was defined to 
designate a cell as a MSC. They must be plastic adherent, express CD90, CD105 and CD73 
on their cell surface, lack the expression of CD45, CD34, CD14, CD79 and HLA-DR and 
have tri-lineage (adipocytes, chondrocytes and osteoblasts) differentiation potential in vitro 
(Dominici et al., 2006). However, it was observed that MSCs express different levels of 
these markers and are variable in their differentiation potential which might be dependent 
on the donor, tissue of origin, isolation technique, culture conditions and passage number 
(Ankrum et al., 2014). 
The origin of MSCs is not well defined. However, there are several reports demonstrating 
that they might be derived from neural crest or mesoderm during development (Morikawa 
et al., 2009; Dennis & Charbord, 2002). Mesoderm originated MSCs have a common 
progenitor with endothelial cells and it has been shown that vascular endothelial cells can 
transform into multipotent stem like-cells via a mutant ALK2 receptor dependent 
mechanism (Medici et al., 2010) indicating that endothelial cells might be a source of 
MSCs after embryonic development. Interestingly perivascular cells, namely pericytes, 
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have also been reported to express MSC markers and have the tri-lineage differentiation 
potential which might designate the progenitor cells derived from blood vessel walls as the 
origin of MSCs (Crisan et al., 2008). However, these studies still require further 
investigation due to the lack of standardization in the handling of MSCs and the lack of 
rigorous in vivo data.  
 
1.3.2. Physiological roles of MSCs 
Although, the information about the stemness, origin and plasticity of MSCs is not 
complete yet, the physiological functions of these cells and especially of bone marrow 
derived MSCs (BM-MSCs) have been extensively studied. MSCs exert their functions 
either by differentiating into downstream lineages or by interacting with other cells directly 
or through paracrine mechanisms. In the bone-marrow, for example, BM-MSCs contribute 
to the homeostasis of the hematopoiesis via the osteoblasts which play a crucial role in the 
bone-marrow microenvironment by creating a niche for hematopoietic stem cells (HSCs) 
(Wilson & Trumpp, 2006). Also, they have been reported to directly interact with HSCs 
and be involved in the organization of their niches (Méndez-Ferrer et al., 2010).  
Apart from the tri-lineage differentiation and direct interactions with the other cells, the 
major action mechanism of MSCs is the production and secretion of a wide range of 
cytokines and growth factors. These factors are produced under different conditions in  
response to different stimuli and have the potential to modulate several cellular processes 
including but not limited to cell proliferation, survival and migration (Table 3). 
 
Table 3 The major paracrine factors secreted by MSCs and their roles in the cellular processes  
Paracrine factors Biological functions 
VEGF, HGF, STC-1, SDF-1, TGFβ, IGF1, bFGF, TB-4 
 
Cell Survival 
VEGF, bFGF, IL-1, TNF-α, PDGF-BB, Ang-1, Ang-2, FGF-
2, TGFβ, SDF-1, IGF-1, PIGF, MCP, HGF 
 
 
 
 
 
Angiogenesis 
VEGF, FGF-2, HGF, IGF-4, TB4 Anti-apoptosis 
VEGF, HGF, IGF-1, TNF-α, TGFβ, G-CSF, SCF, LIF, M-
CSF, IL-6, IL-11, Activin A 
 
Cell differentiation 
BDNF, NGF, neuregulin.1, BNP, IL-6, FGF-2, GDNF, VEGF, 
HGF, FGF-20 
Neuroprotection and 
regeneration 
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One of the well-known outcomes of this wide secretome of MSCs is their impact on the 
immune system. MSCs have immune-suppressive effects on both adaptive and innate 
immunity. They have been shown to suppress T-cell proliferation and activation in vitro 
by secreting IL-10, TGFβ and HGF (Di Nicola et al., 2002; Tse et al., 2003). MSCs also 
inhibit the maturation of dendritic cells, the proliferation and activation of B-cells and 
natural killer cells via paracrine mechanisms (Beyth et al., 2005; Deng et al., 2005; 
Krampera et al., 2006). Moreover, in line with their immune-suppressive properties, MSCs 
can promote the generation of regulatory T-cells and M2 macrophages (Di Ianni et al., 
2008; François et al., 2012). While inhibiting the effector cells of the immune system, 
MSCs themselves were for long believed to be immune privileged. They do not express 
major histocompatibility complex-II (MHC-II) or co-stimulatory molecules such as CD80, 
CD86 or CD40 and they express low levels of MHC-I. Thus they are poorly recognized by 
T-cells (Ryan, Barry, Murphy, & Mahon, 2005). One of the possible clinical applications 
of this feature is to use them as immune suppressors in organ transplantation or in 
autoimmune diseases (Tyndall, 2012). However, it should be mentioned that there are 
recent reports showing that allogeneic MSCs can cause an immune response and it has been 
stated that MSCs should be defined as immune evasive but not as immune privileged 
anymore (Ankrum et al., 2014). Another important function of MSCs is their tropism to 
the damaged tissues and participation in the wound healing process. There are several 
studies showing the homing ability of MSCs to the injury site after their systemic or local 
delivery in different hosts (Chen et al., 2001; Devin et al., 2003). Inflammatory chemokines 
released from the injured tissue facilitate the migration of MSCs since they express various 
chemokine receptors on their surface (Ponte et al., 2007). Although the exact molecular 
mechanisms of homing of MSCs is still under investigation, it has been shown that the 
extravasation process is similar to the well-known leukocyte homing (Rüster et al., 2006). 
IL-1, IL-10, TB-4, MMP-2, MMP-9, MCP-1, TSP-1, TGFβ, 
TIMP-1, TIMP-2, TIMP-9, HGF. NGF, ErbB-2 
Tissue remodeling 
VEGF, bFGF, FGF-2, HGF, TB-4, IGFBP-7 Cell contractility 
IL-6, IL-10, IL-1β, TGFβ, INF-γ, GM-CSF, PGE-2, IDO, 
HGF, TNF-α, Activin A  
Immunomodulatory effects 
VEGF, endothelin, Smad-4, Smad-5, glypican-3, FGF-16 Cell proliferation and 
migration 
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Once MSCs are in the injury site, they can be involved in each phase of wound healing by 
secreting factors such as VEGF, PDGF, bFGF, EGF, and TGFβ and thus directly facilitate 
tissue repair (Maxson et al., 2012). 
 
1.3.3. Roles of MSCs in the tumor microenvironment  
The tropism of MSCs towards the inflammatory signals also makes them migrate to the 
tumor site because tumors continuously produce inflammatory molecules that maintain the 
tumor microenvironment as mentioned above. BM-MSCs expanded ex vivo and injected 
into tumor bearing mice have been shown to accumulate at the sites of solid tumors 
including breast (Dwyer et al., 2007), lung (Suzuki et al., 2011), pancreatic (Beckermann 
et al., 2008), colon (Shinagawa et al., 2010) and ovarian carcinomas (Komarova et al., 
2010) as well as other tumor types such as melanoma (Studeny et al., 2002), glioma 
(Nakamizo et al., 2005), and osteosarcoma (Xu et al., 2009). MSCs that are injected into a 
tumor bearing mice have been shown to migrate to the tumor site though different 
mechanisms. Adhesion of MSCs to the vascular endothelial cells and the following 
extravasation are among the first steps in the homing of circulating MSCs to the tumor site. 
TNFα, which is present in the tumor microenvironment at high concentrations, induces the 
expression of VCAM-I on the surface of MSCs and facilitate the adhesion of these cells to 
the vascular endothelium (Uchibori et al., 2013). The main source of TNFα in the tumor 
microenvironment of invasive breast carcinomas is the tumor associated macrophages 
(Leek et al., 1998) but also breast cancer cells secrete this factor (Meng et al., 2001). It has 
been reported to be highly expressed in the stroma of breast carcinomas and its expression 
has been correlated with the tumor grade (Miles et al., 1994). It has been shown that not 
only inflammatory cytokines and chemokines such as IL-6, IL-8, SDF-1, MCP-1, CXCL-
1, CXCL-2 and TGFβ secreted by tumor tissue but also tumor derived growth factors 
including EGF, HGF, bFGF and PDGF can induce mobilization and migration of MSCs 
(Barcellos-de-Souza et al., 2013). Moreover, hypoxia has been reported to be an important 
factor in MSC homing. HIF-1 secreted by the tumor causes the expression of CXCR3 and 
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CXCR5 on the surface of the cancer cells thus facilitating the recruitment of MSCs which 
produce high levels of CXCL10 and CXCL5 (Chaturvedi et al., 2013).  
The role of MSCs in cancer progression is highly controversial because there are reports 
showing both tumor promoting and suppressing effects of MSCs (Table 2). One of the 
important studies demonstrating tumor promoting roles of MSCs has been performed in a 
breast cancer model. Co-injection of BM-MSCs together with different breast cancer cell 
lines into immune-compromised mice enhanced the metastatic potential of all the cancer 
cell lines by CCL5 secretion that activates Akt signaling in the cancer cells (Karnoub et al., 
2007). 
 
Table 4 Tumor promoting and suppressing effects of BM-MSCs BM-MSCs can promote tumor 
progression by regulating several processes in the tumor microenvironment via secreting several 
cytokines and growth factors. However, there are also several reports showing their anti-
tumorigenic functions (modified from Klopp et al., 2011). 
Tumor 
promoting 
effects 
Isolation Tumor model Findings Proposed mechanism 
Karnoub et 
al. 
Human 
BM-MSC 
Breast 
Increased size and 
increased 
metastasis 
CCL5 secretion 
Zhu et al., 
Fetal and 
adults 
BM-
MSCs 
Colon 
Increased 
incidence 
Enhanced proliferation 
and angiogenesis 
Djouad et al. 
Mouse 
BM-MSC 
Melanoma 
Increased 
incidence 
Immune system related 
Muehlberg et 
al., 
Human 
and 
mouse 
ASCs 
Breast Increased size SDF-1 secretion 
Yu et al. 
Human 
ASC 
Lung or glioma Increased size Reduced apoptosis 
Galie et al. 
Mouse 
ASC 
Breast 
Increased 
incidence and size 
Vasculogenic 
Lin et al. 
Human 
ASC 
Prostate 
Increased 
incidence and size 
Vasculogenic and 
modulation of CXCR4 
Kucerova et 
al. 
Human 
ASC 
Melanoma and 
glioblastoma 
multiforme 
Decreased latency 
and increased size 
of melanoma 
xenografts 
VEGF and SDF-
1a/CXCR4 
Shinagawa et 
al. 
Human 
MSC 
Colon 
Increased size and 
metastasis 
Increased angiogenesis 
and reduced apoptosis 
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In an osteosarcoma model, BM-MSCs have been reported to increase proliferation by 
inducing STAT3 signaling in cancer cells via the secretion of IL-6 (Tu et al.,  2012). IL-6 
secretion by MSCs has been also shown to increase the number of tumor initiating cells in 
colorectal cancer (Tsai et al., 2011).  Further, MSCs can contribute to EMT by secreting 
TGFβ. Breast cancer cells have been reported to express EMT specific markers upon co-
culture with BM- MSCs (Q. Xu et al., 2012).  
On the other side, there are several studies showing tumor growth inhibitory effects of 
MSCs. It has been shown that, for example, BM-MSCs inhibit in vivo tumor growth and 
in vitro proliferation, migration and invasion of lung adenocarcinoma cells by secreting 
oncostatin-M which is a cytokine that promotes differentiation (Wang et al., 2012). Their 
heterogeneity is the most likely explanation for different effects of MSCs on the tumor 
growth. It has thus been speculated that the origin of MSCs, passage number and culture 
conditions might create this difference. Another important factor might be the timing at 
which MSCs are introduced into the tumor microenvironment because when MSCs were 
introduced into the already established tumors, they had growth inhibitory effects. 
Tumor 
suppressing 
effects 
Isolation Tumor model Findings Proposed mechanism 
Ohlsson et 
al. 
MPC1cE 
MSC 
Colon 
Tumor size 
smaller 
Increased inflammatory 
infiltrate 
Khakoo et al. 
Human 
BM-MSC 
Kaposi sarcoma 
Tumor size 
smaller 
AKT signaling 
Qiao et al. 
Human 
fetal skin 
Hepatoma 
Tumor size 
smaller 
Wnt signaling 
Qiao et al. 
Human 
fetal skin 
Breast  
Increased latency, 
reduced tumor 
size and 
metastasis 
Wnt signaling 
Otsu et al. 
Rat BM-
MSC 
Melanoma 
Tumor size 
smaller 
Inhibition of angiogenesis 
Maestroni et. 
al 
BM-MSC 
Lung and 
melanoma  
Tumor size 
smaller and 
decreased 
metastasis 
Increased by treatment of 
MSC with GM-CSF 
Dissertation   Neşe Erdem 
 
 
43 
However, in reports demonstrating tumor promoting roles of MSCs, they were always co-
injected together with the tumor cells (Klopp et al., 2011). 
It should be noted that most of these studies have been done either in vitro by co-culturing 
MSCs together with cancer cells or in vivo injecting in vitro cultured MSCs into tumor 
bearing mice. Therefore, they do not answer the question how bone marrow derived MSCs 
behave intrinsically when there is a solid tumor in the body. There have been two studies 
addressing this issue that are discussed in the following chapter. 
 
1.3.4. MSCs as a source of CAFs 
Cultured MSCs not only have morphological features similar to fibroblasts but also can 
be activated upon proper stimuli, produce ECM proteins and secrete various cytokines 
and chemokines (Kalluri, 2016). It was not clear until recently whether also MSCs 
contributed to CAF population in the tumor microenvironment. Initial studies have been 
reported that MSCs could gain activated phenotype in defined conditions and resemble 
CAFs. First of all, MSCs co-cultured with human colon cancer cells in the presence of 
TGFβ have been reported to express αSMA (Emura et al., 2000). Furthermore, when MSCs 
were exposed to tumor conditioned medium, they gain a CAF-like myofibroblastic 
phenotype such as expression myofibroblast markers and promoting tumor growth (Mishra 
et al., 2008). More recent in vivo studies investigating presence of endogenous bone 
marrow MSCs in the tumor microenvironment have finally proven the fact that MSCs 
indeed can migrate from bone marrow to the tumor microenvironment and contribute to 
CAF population. The first study carried out in an inflammation induced gastric cancer 
mouse model has demonstrated that 20% of CAFs in gastric cancer microenvironment have 
bone marrow origin (Quante et al., 2011). Similarly, also in a breast cancer mouse model, 
bone marrow derived MSCs have been shown as a substantial source of CAFs in the breast 
cancer microenvironment (Yaz et al., 2018).  
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1.4. Aims of the study 
 
Part 1  
The tumor microenvironment (TME) is now recognized as an important factor in breast 
cancer progression and significantly determines the response to anti-cancer therapies. 
Fibroblasts are activated in the early stages of oncogenesis and remodel the TME as an 
early tissue repair response and later these fibroblasts get transformed into cancer 
associated fibroblasts (CAFs) that have been reported to contribute breast cancer 
progression by different means. The mechanisms underlying this transformation of 
fibroblasts from normal activated fibroblasts to CAFs remain largely unknown. Although 
TGF and Wnt signaling pathways have both been associated with fibroblast activation, 
their role in this further transformation into CAFs is not clear. Gaining further insights into 
the activation of fibroblasts could offer a deeper understanding of their origin, plasticity 
and function within the tumor microenvironment. Furthermore, it creates opportunities to 
reverse this activation as a therapeutic option without depleting certain subpopulations of 
CAFs that might result in undesired effects on tumor progression. 
Therefore, the aim of the first part of this PhD project was to understand how the changes 
in CAFs during the activation process are regulated at molecular level via 
 
1. Treating bone marrow derived MSCs with conditioned media of MDA-MB-231 
cells to induce a CAF-like activated fibroblast phenotype. 
2. Performing gene expression and secretome analysis to find out differentially 
expressed genes and differentially secreted factors upon activation. 
3. Identifying target genes that might have a role in the activation of fibroblasts. 
4. Validating their effect on already activated patient derived CAFs. 
5. Elucidating molecular mechanism underlying their effect on the activation of 
fibroblasts by profiling their impact on signaling pathways. 
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Part 2 
 
Bone marrow MSCs have been identified as a substantial source of CAFs in breast cancer 
and reported to migrate from bone marrow to the breast TME. Bone marrow MSCs are a 
heterogeneous population consisting of stromal cells that support hematopoiesis and stem 
cells that could generate skeletal lineages. In the case of cancer, it is still not clear whether 
there is a preference for a specific subpopulation to be recruited to the tumor side and once 
there having been activated, to contribute to the CAF population. Moreover, the molecular 
mechanisms behind the activation of MSCs to become CAFs are a topic of ongoing 
research.   
Therefore, the aim of the second part of this PhD project was to characterize MSCs 
migrating to the tumor microenvironment using a syngeneic mouse model via 
 
1. Identifying the subpopulation(s) of bone marrow MSCs migrating to the breast 
cancer microenvironment by transplanting different stromal subsets into tibia of a 
breast tumor bearing mouse and monitoring their migration to the tumor 
microenvironment. 
2. Profiling the changes in MSCs once they are in the tumor microenvironment by 
isolating MSCs from tibia or breast tumor to analyze the differences in their gene 
expression and DNA methylation levels.  
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Laboratory equipment 
Aushon 2470 contact printer Aushon Biosystems 
Cell counter CASY CASY, Roche 
Cell culture incubator Binder 
Flow cytometry FACS Canto II  Becton Dickinson 
Freezer (-20 °C)  Liebherr 
Freezer (-80 °C) Sanyo 
Fridge Liebherr 
Laminar flow hood HERA safe, Thermo Scientific 
Light Microscope Hund Wetzlar 
Micro pipettes Gilson 
Microplate reader Glomax Microplate Reader 
Microvolume UV-Vis 
spectrophotometer 
 
Nanodrop ND-1000, Thermo Scientific 
Molecular Devices microscope IXM 
XLS 
Molecular Devices 
Near Infrared Scanner Odyssey LI-COR Biosciences 
PCR machine Gene Amp PCR systems, Applied 
Biosciences 
Pipetboy Integra 
Power supply  Consort 
TaqMan reader ABI Prism7900HT, Applied Biosystems 
Table top centrifuge Biofuge fresco, Heraeus 
Vacuum aspirator Laboport, KNF 
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Vortex mixer Heidolph 
Water bath Julabo 
 
2.1.2 Consumables 
Adhesive Optically Clear Plate Seal  
 
Thermo Fisher Scientific 
Cell culture flasks (75 cm2 and 175 cm2) Greiner Bio-one 
Cell scraper  Corning 
Cryo vials Nunc, Thermo Fisher Scientific 
Disposable Filtertips for micro pipettes Starlab 
Disposable tips for micro pipettes Steinbrenner 
Oncyte® Avid Nitrocellulose Film-Slide  
 
Grace Bio-Labs 
Optical 384ßwell plates for TaqMan Applied Biosystems 
PCR strips Steinbrenner Laborsysteme GmbH 
PVDF blotting membrane Immobilon-P, millipore 
RTCA CIM plates Roche Diagnostics 
Serological pipettes BD Falcon 
Trans-well system  Corning 
1.5 ml microcentrifuge tubes Eppendorf AG 
2 ml microcentrifuge tubes Eppendorf AG 
15 ml conical tube Becton Dickinson 
50 ml conical tube Becton Dickinson 
6-well cell culture plate  Greiner Bio-one 
96-well cell culture plate  Greiner Bio-one 
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96-well plate (ELISA) Greiner Bio-one 
 
2.1.3. Chemicals and reagents 
BSA PAA 
CasyTon Roche 
Chloroform Sigma-Aldrich 
Cholera toxin Sigma-Aldrich 
Complete Mini Protease Inhibitor Cocktail  
 
Roche 
CytoPerm-CytoFix Becton Dickinson 
DMSO Sigma-Aldrich 
DMEM-F12 medium 
 
Gibco 
Ethanol Sigma-Aldrich 
Fast Green FCF Carl Roth 
Fetal Bovine Serum Gibco 
Hoechst 33258 Sigma 
Lipofectamine RNAi max Invitrogen 
DMEM medium Gibco 
Methanol Sigma-Aldrich 
M-PER protein extraction reagent 
 
 
Rockland 
Nuclease-free water Ambion 
Opti-MEM 
 
Gibco 
PBS Gibco 
Pen/Strep Gibco 
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Perm/Wash Becton Dickinson 
Proteinase K Sigma-Aldrich 
Rockland Blocking Buffer Rockland Immunochemical Inc. 
SDS 
 
 
 
 
Carl Roth 
Sodium fluoride (NaF) Sigma-Aldrich 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich 
TaqMan Fast Universal PCR Master Mix 
(2x) 
Applied Biosystems 
Trypsin-EDTA 
 
 
Sigma-Aldrich 
Tween 20 Sigma-Aldrich 
Universal Probe Library Roche 
 
2.1.4. Solutions 
Blocking buffer 
(ELISA) 
PBS with 1% BSA 
 
 
Blocking buffer 
(RPPA) 
1:1 Rockland blocking buffer: TBS 
1 mM Na3VO4 
10 mMNaF 
 
FCF staining 
solution 
0.005% Fast Green FCF 
10% acetic acid 
30% ethanol 
FCF destaining 
solution 
10% acetic acid, 
30% ethanol 
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Luciferase 
Buffer 
40 mM Tricine 
2 mMATP 
10 mM MgSO4 
0.5 mM EDTA 
10 mM DTT 
1 mM CoA 
1 mM Luciferin 
Protein Lysis 
Buffer 
M-PER lysis buffer 
1x Complete Mini Protease Inhibitor Cocktail 
1x PhosSTOP Phosphatase Inhibitor Cocktail 
1 mM Na3VO4 
10 mMNaF. 
 
 
 
Printing Buffer 
(RPPA) 
10% glycerol 
4% SDS 
10 mM DTT 
125 mM Tris–HCl pH 6.8 
Staining buffer 
(FACS) 
PBS with 2% FBS 
Washing buffer 
(ELISA) 
PBS with 0.25% Tween 20 
 
2.1.5. Commercial kits 
BCA Protein Assay Kit 
Pierce 
 
DNasey Blood and Tissue Kit Qiagen 
Human Stanniocalcin 1 DuoSet ELISA R&D Systems 
Lineage Cell Depletion Kit MACS, Miltenyi 
RNeasy Mini Kit Qiagen 
ReverdAid H Minus First Strand cDNA Synthesis 
Kit  
Thermo Scientific 
TaqMan  Applied Biosystems 
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2.1.6. Cells and growth media 
 
Cell lines Source Derived from Growth media 
HCC-1937 ATCC CRL-2336 
Breast ductal 
carcinoma 
DMEM-F12 with 
10% FBS and 1% 
PenStrep 
HS578T ATCC HTB-126 Breast carcinoma 
MCF7 ATCC HTB-22 
Breast 
adenocarcinoma 
MDA-MB-231 ATCC HTB-26 
Breast 
adenocarcinoma 
T47D ATCC HTB-133 
Breast ductal 
carcinoma 
Primary cells   
Mesenchymal 
Stromal Cells 
LONZA 
Isolated from bone 
marrow 
CAF1 cells Patient material Breast tumor 
CAF2 cells  Patient material Breast tumor 
 
 
 
2.1.7. siRNAs  
siRNA pools composed of four different siRNA sequences against a specific target gene 
were picked from the human siRNA library of siOnTargetPlus (Dharmacon) 
 
Gene name Catalogue number  
Number 
Annotations Target sequences 
STC1 pool 
LU-006477-00-
0002 
siSTC1 
AAACGCACAUCCCAUGAGA 
GGGAAAAGCAUUCGUCAAA 
GUACAGCGCUGCUAAAUUU 
CAACAGAUACUAUAACAGA 
 
ON-
TARGETplus 
non- targeting 
pool 
D-001810-10-20 siCTRL 
UGGUUUACAUGUCGACUAA  
UGGUUUACAUGUUGUGUGA  
UGGUUUACAUGUUUUCUGA  
UGGUUUACAUGUUUUCCUA  
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2.1.8. TaqMan qRT-PCR primers and probes 
Gene Forward Primer Reverse Primer Probe number 
IL-6 gatgagtacaaaagtcctgatcca 
 
ctgcagccactggttctgt 
 
40 
IL-8 agacagcagagcacacaagc 
 
atggttccttccggtggt 
 
 
72 
MMP1 gctaacctttgatgctataactacga tttgtgcgcatgtagaatctcg 7 
MMP2 tacgaccgcgacaagaagta 
 
agttcccaccaacagtggac 
 
29 
MCP1 agtctctgccgcccttct 
 
gtgactggggcattgattg 
 
40 
STC1 aagccatcactgaggtcgtc caggcttcggacaagtctgt 44 
 
2.1.9. Antibodies 
2.1.9.1. FACS antibodies  
 
 
 
2.1.9.1. MACS depletion antibodies  
 
 
 
 
 
Protein Company/Catalogue number Dilution 
FAP-PE RnD, FAB3715P-025 1:20 
PE-isotype RnD, FAB3715P-025 1:20 
SMA -eflour660 eBiosciences, 50-9760-82 
 
 
1:1000 
eflour660-isotype eBioscineces, 50-4724-80 1:1000 
CD45-PerCP Biolegend, 103129 
 
1:200 
PerCP-isotype Biolegend, 400629 
 
1:200 
Ter119-PerCP Biolegend, 116225 1:200 
CD31-APC Biolegend, 102409 1:80 
APC-isotype Biolegend, 400511 1:80 
PDGFRa-PeCy7 Biolegend, 135911 1:150 
PECy7-isotype Biolegend, 400557 1:150 
CD51-PE Biolegend,104105 1:20 
PE-isotype Biolegend, 400407 1:20 
Protein Company/Catalogue number Dilution 
CD45 
 
RnD, FAB3715P-025 1:400 
CD31 RnD, FAB3715P-025 1:200 
Ter119 eBiosciences, 50-9760-82 
 
 
1:100 
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2.1.9.2. RPPA antibodies 
Protein name catalog # Protein name catalog # Protein name catalog # 
CSNK1E CST_12448 CSNK1E CST_12448 Cdk2 Sigma C5223 
Phospho-
AMPKalpha_Thr172_
40H9 CST 2535 
Phospho-
AMPKalpha_Thr172_
40H9 
CST 2535 Phospho-c-
Raf_Ser259 CST 9421 
p53_DO-1 sc 126 
p53_DO-1 sc 126 
Smad4 
Millipore 
MAB1132 
pak1 CST 2602 pak1 CST 2602 GSK-3alpha CST 9338 
beta-Catenin CST 9562 beta-Catenin CST 9562 APC CST 2504 
ERK5 CST3372 ERK5 CST3372 c-Myc ab32072 
Phospho-elF4B 
_Ser406 CST 5399 
Phospho-elF4B 
_Ser406 
CST 5399 
Phospho-
PRAS40_Thr246_C
77D7 CST 2997 
Caspase-9_Human 
Specific CST 9502 
Caspase-9_Human 
Specific 
CST 9502 
Phospho-
PTEN_Ser380_Thr3
82-383_44A7 CST 9549 
IkappaB-alpha CST 9242 IkappaB-alpha CST 9242 ADAM9_D64B5 CST 4151 
MEK1 BD 610122 
MEK1 BD 610122 
Phospho-
PKCalpha_Ser657 
Millipore 06-
822 
p27_Kip1 BD 610241 p27_Kip1 BD 610241 ERK 2_6G11 sc 81458 
PIK3CB ab32569 
PIK3CB ab32569 
Phospho-c-
Jun_Ser73 CST 9164 
Phospho-beta-
Catenin_Ser675 CST 9567 
Phospho-beta 
Catenin_Ser675 
CST 9567 
Axam 
Sigma 
HPA029247 
Phospho-MAP Kinase 
Kinase 1-2_MEK1-
2_phosphoserine 217-
220 CST 9154 
Phospho-MAP Kinase 
1-2 
CST 9154 
mTOR CST 2972 
Bcl-xL_54H6 CST 2764 Bcl-xL_54H6 CST 2764 PP2A B Subunit CST 4953 
Phospho-
MEK1_Ser298 CST 9128 
Phospho-
MEK1_Ser298 
CST 9128 
S6 Ribosomal 
Protein_5G10 CST 2217 
Met_L41G3 CST 3148 Met_L41G3 CST 3148 PKAalpha cat_C-20 sc 903 
Rap1Alpha 
Abcam 
ab124963 
Rap1Alpha 
Abcam 
ab124963 BRAF CST 9434 
LRP5_D80F2 CST 5731 LRP5_D80F2 CST 5731 P44/42 CST9102 
Phospho-p38 
MAPK_Thr180-
Tyr182_3D7 CST 9215 
Phospho-p38 MAPK CST 9215 
Caveolin 1 ab32577 
Akt2_D6G4 CST 3063 Akt2_D6G4 CST 3063 AMPKalpha CST 2532 
Phospho-NF-kappaB 
p65_Ser536_93H1 CST 3033 
Phospho-NF-kappaB 
p65_Ser536_93H1 
CST 3033 
TACE_D22H4 CST 6978 
c-Raf CST 9422 
c-Raf CST 9422 
S6K1_phospho 
T421_S424_E135 ab 32525 
MLCP sc-7482 MLCP sc-7482 PKCdelta_D10E2 CST 9616 
Dishevelled 
3_EP1991Y ab 76081 
Dishevelled 
3_EP1991Y 
ab 76081 
Akt BD 610860 
c-Jun_60A8 CST 9165 c-Jun_60A8 CST 9165 p38 MAPK  CST9212 
PDK1 CST 3062 PDK1 CST 3062 c-FOS sc-7202 
PP2A A Subunit CST 2039 PP2A A Subunit CST 2039 CSNK2A1 CST_2656 
GRB2 CST 3972 
PI3 Kinase p85 
alpha_ep380y ab 40755 ROCK2 
atlas antibodies 
HPA007459 
DKK1_4D4 
WH0022943
M1 p70 S6 Kinase_49D7 CST 2708 
Phospho-
PDK1_Ser241 CST 3061 
Phospho-mTOR_Ser 
2448 CST 2971 CDH1 CST 4065 JNK1_2C6 CST3708 
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Crk CST 3492 pSMAD3 CST 9520 
Tuberin_TSC2_D57
A9 CST 3990 
Jagged1_28H8 CST 2620 RBPSUH CST 5442 Notch2_D67C8_XP CST 4530 
HER2/ErbB2_29D8 CST 2165 CBP_D6C5 CST7389 Snail CST 3895 
ILK CST 3862 
Phospho-
MSK1_Ser376 CST 9591 DIAPH1 CST 5486 
p70 S6 Kinase 
Phospho_pT421-
pS424 
Epitomics 
1135-1 EGF Receptor CST 2646 Jagged2_C23D2 CST 2210 
Nicastrin CST 5665 Src_32G6 CST 2123 Snail CST 3879 
HER4_ErbB4 
Phospho_pY1162 
Epitomics 
2295-1 TCF7_EPR2035 ab 134127 Axin1_C7B12 CST 3323 
pSMAD2 CST 3108 Smad6 CST 9519 
Lunatic 
Fringe_D6V2V CST66472 
CDK7 CST 2090 
Phospho-EGF 
Receptor_Tyr1086 CST 2220 
Phospho-HER3-
ErbB3_Tyr1289_21
D3 CST 4791 
PEN2_D6G8 CST 8598 
Phospholipase C 
gamma 1_M156 ab 41433 pSMAD2/3 sc-11769-R 
NLK_EPR2012_3 ab 154200 Wnt16 ab 109437 LKB1_27D10 CST 3050 
MSK2_D41A4_XP CST 3679 Stat5_3H7 CST 9358 
PLC Gamma I 
Phospho_pY771 
Epitomics 2350-
1 
Gab3 CST 3232 
Phospho-EGF 
Receptor_Tyr845 CST 2231 ErbB4 ab76303 
Phospho-p44/42 
MAPK_ERK1-
2_Thr202-Tyr204 CST 4370 MEK7_EP1455Y ab 52618 
Phospho-Src 
Family_Tyr416 CST 2101 
eIF4B CST 3592 NF-kappaB p65 CST 3034 
CTNNBIP1_EPR66
97_2 ab 129011 
p21_C-19 sc 397 Phospho-Stat3_Tyr705 CST 9131 pEGFR_Tyr1148 CST 4404 
Phospho-S6 
Ribosomal 
Protein_Ser240-244 CST 2215 IKKa CST 11930 c-Cbl CST 2747 
Stat3 BD 610189 cyclin D1_M-20 CST 2926 NLK_EPR2012_2 ab 154199 
CDK4_DCS156 CST 2906 rhoa CST 2117 MSK2_D41A4_XP CST 3679 
pak2 ab76293 LRP6 ab 134146 Gab2 CST 3232 
FAK CST 3285 ERK1 RnD AF1575 
Phospho-Src 
Family_Tyr417 CST 2101 
Phospho-
MEK1_Thr286 CST 9127 
PI3 Kinase p110 
beta_Y384 ab 32569 
CTNNBIP1_EPR66
97_3 ab 129012 
4E-BP1_53H11 CST 9644 Phospho-cdc2_Tyr15 CST 9111 pEGFR_Tyr1149 CST 1090 
CREB _48H2 CST 9197 Rac1-2-3 CST 2465 c-Cbl CST 567 
MEK4 ab 33912 
casein kinase 
IIbeta_6D5 (CSNK2B) sc 12739 pSMAD2 
566415 
Calbiochem 
Ras, clone RAS10 
Millipore 05-
516 
PI3 Kinase 
p110alpha_C73F8 CST 4249 MSK2_D41A4_XP CST 3679 
IGF-IR_clone 
JBW902 
Millipore 05-
656 SOS CST 12409 Gab1 CST 3232 
Paxillin CST 2542 Smad3_C67H9 CST 9523     
 
2.1.10. Software 
BD FACS DIVA BD Biosciences 
Graph Pad Prism 7.0 GraphPad Software, Inc.  
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Image J  NIH 
Inkscape Software Freedom Conservancy, Inc.  
Odyssey 2.1  LI-COR 
Roche UPL Design Center 
 
Roche Diagnostics 
SDS 2.2 Applied Biosystems 
xCelligence Real Time Cell Analyzer 
Software 1.2 
Roche Diagnostics 
 
2.1.11. Databases 
TCGA mRNA 
data  
 
TCGA_BRCA_exp_HiSeqV2-2015-02-24  
 
GSE14548 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14548 
GSE35019 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35019 
GSE9014 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9014 
GSE5847 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE5847 
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2.2. Methods 
2.2.1. Cell culture  
2.2.1.1. Cultivation of cells 
All breast cancer cell lines were obtained from ATCC. Cell lines were regularly 
authenticated by multiplex cell line authentication (Multiplexion GmbH, Friedrichshafen, 
Germany) and tested for mycoplasma contamination. Breast cancer cell lines used in co-
culture experiments were modified by Ana Maia to express H2B tagged with yellow 
fluorescent protein. MSCs belonging to different donors were purchased from Lonza. 
CAFs were isolated from patient samples by Mireia Berdiell. All cells were incubated in a 
humidified incubator at 37 °C and 5% CO2. Primary cells that are MSCs and CAFs were 
split when they reached to 80% confluency and medium was changed in every 3 to 4 days. 
They were used up to passage 9. Breast cancer cell lines were passaged every three to four 
days. To detach the cells, they were first washed with PBS and incubated with 0.25 % 
trypsin-EDTA. After detachment, trypsin was inactivated by the addition of full growth 
medium. Cells were counted using the CASY cell counter by counting 50µl of cell 
suspension diluted in 10ml CASYton. Cell were frozen in 1.5ml cryovials in an isopropanol 
bath at -80 °C using full growth media supplemented with 10% DMSO and additional 10% 
FBS. Frozen vials of cells were recovered by thawing quickly in a 37 °C water bath. Table 
5 shows the cell numbers that were used in culture conditions and experimental conditions 
according to different flask types.  
 
Table 5 Cell numbers in culture and experimental conditions 
 Culture conditions Experimental conditions 
MSCs 75 cm2 flasks: 4 x105 
 
6 well plates: 5-8x104 
10 cm dishes: 1.6-2.5 x105 
96 well plates: 500-1000 
CAFs 10 cm dishes: 2.5 x105-4 x105 6 well plates: 5-8x104 
96 well plates: 500-1000 
Breast cancer cell lines 10 cm dishes: 2.5 x105-4 x105 10 cm dishes 
96 well plates: 300-500  
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2.2.1.2. Generation of conditioned media of MDA-MB-231 cells and treatment of MSCs    
with conditioned media 
1x106 MDA-MB-231 cells were seeded in 10 cm dishes in 10 ml DMEM-F12 
supplemented with 1% FBS. Supernatant from the dishes was collected after 72 h and 
centrifuged in 1800 rpm and filtered using 0.25 uM filters to remove death and floating 
cells. Conditioned media was kept in -80 °C and thawed only once before treating MSCs. 
1.6x105 MSCs were seeded in 10 cm dishes and treated either with DMEM-F12 
supplemented with 1% FBS or conditioned media of MDA-MB-231 cells for 3, 7 or 14 
days. Media or conditioned media was changed every 3-4 days. 
 
2.2.1.3. In-direct co-culture of MSCs and MDA-MB-231 cells using trans-well system 
2.5x105 MSCs were seeded in the lower chamber of 10 cm trans-well dishes in 9 ml 
DMEM-F12 supplemented with 1% FBS. 4x104 MDA-MB-231 cells were seeded in the 
upper chamber in 7 ml DMEM-F12 supplemented with 1% FBS. Trans-well were 
incubated for 3 or 7 days with a medium change every 3-4 days. 
 
2.2.1.4. Transfection 
All transfections were performed using Lipofectamine RNAi max (Invitrogen) transfection 
reagent according to the manufacturer’s instructions. It is a cationic lipid-based method in 
which the positive charge of the liposome mediates the interaction between the nucleic acid 
and the negatively charged cell membrane, resulting in the endocytosis of the transfection 
complex (liposome/nucleic acid) into the cells (Life Technologies, Lipid transfection). 
Table 3 summarizes the amount of the Lipofectamine RNAi max and siRNAs used for the 
different size cell culture plates. 
 
Table 6 Amount of Lipofectamine RNAi max and siRNAs used for transfections 
 
Lipofectamine 
RNAi max 
Final concentration of 
siRNA 
6-well plate 5 µl 30 nM 
10 cm dish 20 µl          30 nM 
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2.2.2. Gene expression analysis  
2.2.2.1. mRNA isolation and reverse transcription 
mRNA was isolated using RNeasy Mini Kit of Qiagen according to manufacturer’s 
protocol. RNA concentration and purity were measured by the NanoDrop-ND 1000 
(Thermo Scientific). To synthesize the cDNAs, 500 ng total RNA was used and reverse 
transcription was performed using RevertAid H Minus First Strand cDNA Sythesis Kit. 
RNA was mixed with 1 µl of oligo dT-Primer to a volume of 12 µl. This mix was incubated 
for 5 min at 70 °C and mixed with 4 µl 5x reaction buffer, 1 µl RiboLock Ribonuclease 
Inhibitor (20 u/µl), 2 µl 10 mM dNTP mix and 1 µl Reverd Aid H Minus-MuIV RT (200u/ 
µl) to a final volume of 20 µl. This mix was incubated for 5 min 37 °C, followed by 60 min 
at 42 °C and 10 min at 70 °C. 
 
2.2.2.2. Taqman qRT-PCR 
To quantify specific genes, primers and probes for TaqMan qRT-PCR were designed using 
the Roche UPL Design Center. cDNA was diluted to 2 ng/µl and 5 µl of this dilution was 
mixed with 5.5 µl Abgene 2x mix, 0.11 µl left and right primers, 0.11 µl probe to a final 
volume of 11 µl. This mixed was incubated for 2 min 50 °C, followed by 15 min at 95 °C 
and 45 cycles of 15 sec at 95 °C and 60 sec 60 °C. The amplification and expression 
analysis were carried out using the ABI prism 7900HT sequence detection system using 
ΔΔCt method. 
 
2.2.2.3. RNA Sequencing data alignment, differential analysis and pathway enrichment 
analysis 
RNA sequencing (RNA-seq) was performed of MSCs treated either with media or 
conditioned media of MDA-MB-231 using Hiseq 4000 Paired-end 100 base pair 
technology by Genomics and Proteomics Core Facility of DKFZ. RNA sequencing 
analysis was performed by Naveed Ishak (Heidelberg Center for Personalised Oncology 
(DKFZ-HIPO)). RNA-seq reads were mapped the human reference genome (build 37, 
version hs37d5) using STAR (version 2.5.2b) [1] using a 2-pass alignment. Duplicate reads 
were marked using sambamba (version 0.6.5) [2] using 8 threads, and were sorted by 
position using SAMtools (version 1.6) [3]. BAM file indexes were generated using 
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sambamba. Quality control analysis was performed using the samtools flagstat command, 
and the rnaseqc tool (version v1.1.8.1) [4] with the 1000 genomes assembly and gencode 
19 gene models. Depth of Coverage analysis for rnaseqc was turned off. featureCounts 
(version 1.5.1) [5] was used to perform gene specific read counting over exon features 
based on the gencode V19 gene model. The quality threshold was set to 255 (which 
indicates that STAR found a unique alignment). Strand unspecific counting was used. For 
total library abundance calculations, during FPKM/TPM expression values estimations, all 
genes on chromosomes X, Y, MT and rRNA and tRNA were omitted as they possibly 
introduce library size estimation biases. 
Differential expression and expression fold change analysis were performed using DESeq2 
(version 1.14.1) [6] and heat maps were visualized by ComplexHeatmap package (version 
1.99.5) [7]. Genes with FDR < 0.05 were considered for further analysis. 
All differentially expressed genes (Benjamini-Hochberg correct p-value < 0.05) with log2 
fold change greater than 2 were used for KEGG enrichment analysis via the DAVID 
webtool. Default parameters were used and both the gene list and background were set to 
homo sapiens for all tests. Benjamini-Hochberg corrected modified Fischer's exact test 
(EASE score) p-values were used to determine if KEGG pathways were significantly 
enriched (Huang et al., 2009) 
 
2.2.3. DNA methylation analysis 
DNA methylation analysis was performed of MSCs treated either with media or 
conditioned media of MDA-MB-231 using Infinium MethylationEPIC Kit by Genomics 
and Proteomics Core Facility of DKFZ. Data analysis to find differentially methylated 
CpGs were carried out by Dr. Yassen Assenov (Post-doctoral researcher in the Division of 
Epigenomics and Cancer Risk Factors, DKFZ) using RnBeads (Assenov et al., 2014).  
 
2.2.4. Protein expression analysis 
2.2.4.1. Analysis of CAF markers by flow cytometry 
Flow cytometry analysis was performed to measure the expression of FAP and SMA at 
protein level. To this end, cells kept in different conditions collected by trypsinization and 
a single cell suspension was generated. 5x105 cells per condition were pipetted into 
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different wells of a deep well plate and washed with staining buffer (PBS supplemented 
with 2% FBS). For surface staining, FAP antibody tagged with PE fluorophore (RnD) was 
used in a 1:2.5 dilution in 100 µl of staining buffer and cells were incubated on ice for 45 
min. Next, cells were washed with 1x PermWash Buffer and incubated with Cytofix 
Cytoperm solution for 10 min on ice to fix and permeabilize the cells before intra-cellular 
staining. For intracellular staining SMA antibody tagged with eFlour660 fluorophore was 
used in a 1:1000 dilution 100 µl of 1x PermWash buffer and cells were incubated on ice 
for 30 min. Cells were again washed with 1x PermWash Buffer and resuspended in 150 µl 
of 1x PermWash buffer. Cells were acquired with BD CantoII cell analyzer and analysis 
was carried out with BD FACS DIVA software.  
 
2.2.4.2. Secretome analysis and intracellular protein analysis by mass spectrometry 
Secretome analysis was performed by Gertjan Krammer (Post-Doctoral Scientist, Division 
of Proteomics of Stem Cells and Cancer) using previously established method (Eichelbaum 
et al., 2012) that enables detection of differentially secreted proteins that are newly 
produced in MSCs upon treatment with media or conditioned media of MDA-MB-231 
cells. This method combines click chemistry and pulsed stable isotope labeling with amino 
acids in cell culture to selectively enrich and quantify secreted proteins. For this, cells are 
labeled with AHA that is incorporated into newly synthesized proteins and replaces 
methionine. Newly synthesized proteins are then coupled to alkyne-functionalized agarose 
resin by 1,3-cycloaddition (click reaction). To quantify secreted proteins another labeling 
with stable isotope-labeled amino acids (SILAC) is carried out. Secreted proteins can be 
then quantified using liquid chromatography tandem mass spectrometry (LC-MS/MS) after 
on-bead digestion and (optionally) peptide fractionation. Labeling with AHA and SILAC 
was carried out in MSCs treated with media or conditioned media of MDA-MB-231 cells 
for 7 or 14 days. While, MSCs treated with media were labeled with intermediate isotype 
labeled arginine and lysine (intermediate channel), MSCs treated with conditioned media 
were labeled with heavy isotype labeled arginine and lysine (heavy channel) making 
possible to quantify differentially secreted proteins among these two conditions. For this, 
1.6x105 MSCs seeded in 10 cm dishes were treated with media or conditioned media of 
MDA-MB-231 cells. At the end of the treatment, MSCs were washed two times by PBS 
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and incubated with depletion media for 30 min. Next, labeling media was pipetted on the 
cells and cells were incubated for 6 hours. At the end of incubation time, supernatants were 
collected and centrifuged in 1800 RPMI for 5 min to remove cell debris and death cells. 
Labeling of the cells were done by me and following sample preparation, measurement and 
analysis were carried out by Gertjan Krammer. Together with supernatants, cell pellets 
were also collected and analysis of differentially expressed intracellular proteins was 
carried out using the same method.  
 
2.2.4.3. Detection of STC1 by ELISA 
Enzyme linked immunosorbent assay (ELISA) is an antigen-antibody interaction based  
technique used to detect and quantify a specific protein in a solution. In this study, it was 
performed to quantify the amount of STC1 in the supernatants of MSCs using Human 
Stanniocalcin 1 DuoSet ELISA kit from R&D Systems according to the manufacturer’s 
protocol. Briefly, 96 well plate was coated with a capture antibody against STC1 and 
incubated over night at room temperature. The next day, blocking was done using PBS 
with 1% BSA for 2h at room temperature. The standards and supernatants diluted in the 
blocking buffer were applied to the wells and incubated for 2h at room temperature. For 
the detection, the wells were incubated first with a biotinylated detection antibody for 2h 
and then with Streptavidin-HRP for 20 min. Afterwards, the wells were incubated with a 
substrate solution of HRP and reaction was stopped by adding stop solution after 20 min. 
The optical density was detected immediately ay 450 nm using Glomax Microplate reader. 
Standard curve was generated using the absorbance value of standards and absolute 
concentration of STC1 in the supernatants of MSCs was calculated.  
 
2.2.4.3. Cell lysis, protein extraction and quantification  
To harvest the cells, the media was removed and the cells were washed with PBS. Protein 
lysis buffer was added and the cells were detached using a cell scraper. Cells were 
incubated in the lysis buffer for 20 min and proteins were separated from the cell debris by 
centrifuging the samples at 13000 rpm for 5 min. Protein concentration was determined 
using the BCA Protein Assay Kit according to the manufacturer’s instructions.  
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2.2.4.4. RPPA 
Reverse Phase Protein Array (RPPA) was performed by Simone Borgoni (Phd student, 
Molecular Genome Analysis, DKFZ) using protein lysates of CAF1 cells transfected either 
with control siRNA or siRNA targeting STC1 mRNA. RPPA is (Paweletz et al., 2001). To 
this end, cell lysates were adjusted to a total protein concentration of 2 μg/μl. Samples were 
mixed with 4 x RPPA printing buffer and denatured at 95°C for 5min. The lysates were 
pipetted into 348-well plates and centrifuged for 2 min at 200 x g. As internal controls a 
dilution series of All samples were printed as technical triplicates on Oncyte Avid 
Nitrocellulose Film-Slides using an Aushon 2470 contact printer with 185 μm solid pins. 
1.6 nl sample per spot was printed with an average spot diameter 250 μm. After the printing, 
slides were kept at -20°C. Before staining, the slides were blocked for 2 h at room 
temperature with blocking buffer. After blocking, the slides were incubated with primary 
antibodies at 4°C overnight. After incubation the slides were washed for 4 times for 5min 
with TBST and subsequently incubated with Alexa Fluor® 680 F(ab')2 fragments of goat 
anti-mouse IgG or anti-rabbit IgG in 1:12000 dilution for 1h at RT in dark. After 4 more 
washing round with TBST, the slides were washed 2 more times for 5 min with ultra-pure 
water. Afterwards, the slides were dried and scanned with the Odyssey® Infrared Imaging 
System with an excitation wavelength of 685nm and a resolution of 21 μm. Total protein 
quantification done using Fast Green FCF protein dye was used for normalization.  
Signal intensities of individual spots were quantified using GenePixPro 7.0 software. The 
TIFF image of each slide and gene pix array list file (generated by the printer to map the 
sample location on the slide) was matched into a gene pix result file. A visual inspection 
of each spot was performed and slides without uniform background signal were excluded 
from further analysis. RPPA raw data preprocessing and quality control were performed 
using the RPPanalyzer R-package (Mannsperger et al., 2010).  The raw signal intensities 
of the control samples were plotted against the respective total protein concentration. Only 
data of antibodies showing a linear correlation between target signal intensity and protein 
concentration were used for further analysis. Afterwards, target signals were normalized to 
the total protein amount per spot via Fast Green FCF control. After median calculation of 
technical replicates, normalized target signal intensities were plotted against the signal 
intensities obtained by incubation of primary antibody controls (blank signal). Machine 
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running, raw data processing and data generation was done by Simone Borgoni and 
antibody incubation and imaging of slides were done by Corinna Becki (Research 
Technician, Division of Molecular Genome Analysis, DKFZ).  
 
2.2.5. Functional assays 
2.2.5.1. Collagen gel contraction assay 
Collagen contractility, a characteristic of activated fibroblasts, can be evaluated by 
Collagen Gel Contraction Assay. Collagen gel contraction assay was performed 
according to a previously published protocol (Su & Chen, 2015). Briefly, cells kept 
in different conditions collected and the concentration was adjusted into 1.5 × 10 5 
cells/mL in DMEM-F12 supplemented with 1% FBS. 400 µl of cell suspension was 
pipetted into 24 well plates and mixed with 200 µl of Collagen type I isolated from rat tail 
(Thermo scientific). 7 µl of 1 M NaOH was added in each well immediately and mixed 
well. The mix was incubated at room temperature for 20 min until solidified and 600 µl of 
DMEM-F12 supplemented with 1% FBS was added into each well and the collagen gel 
was dissociated by gently running the tip of a 200 μL pipet tip along gel edges. The plates 
were incubated in a humidified incubator at 37 °C and 5% CO2 for 24 to 72h and images 
was taken using a scanner. Gel contraction that is proportional to the area of the gel was 
measured using the Image J software. 
 
2.2.5.2. Cell proliferation 
Analysis of proliferation of MSCs by Hoechst staining 
Hoechst as a fluorescent dye can bind to DNA. Total nuclei count can be determined by 
fluorescence microscopy after staining the cells with Hoechst. In this study, different cell 
types were stained with Hoechst -33258 to analyze the changes in their proliferation rate 
upon different conditions. To this end, cells seeded on 96 well plates were stained with 
Hoechst-33258 in 1:5000 dilution in media and incubated at 37c for 30 min. Fluorescent 
images were taken using the Molecular Devices microscope IXM XSL and nuclei counting 
was performed using Molecular Devices Software. The number obtained was considered 
as cell number. MSCs treated with media or conditioned media of MDA-MB-231 cells for 
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3 or 7 days were seeded in 96 well plates (750 cells per well) and after 3 days incubation 
nuclei counting was performed. 
 
Analysis of proliferation of breast cancer cells 
Proliferation analysis was performed using breast cancer cell lines, that were either directly 
co-cultured with MSCs or treated with conditioned media of MSCs or directly co-cultured 
with CAF1 cells. For direct co-culture experiments, MSCs or CAF1 cells were seeded in 
96 well plates (500 cells per well) and next day breast cancer cells that express H2B tagged 
with YFP were seeded on top in DMEM-F12 supplemented with 1% FBS (500 cells per 
well). Fluorescent images were taken using the Molecular Devices microscope IXM XSL 
every day for 5 days. For conditioned media treatment experiments, breast cancer cells 
were seeded in 96 well plates (1×103 cells per well) and next day conditioned media 
treatment was started. Fluorescent images were taken using the Molecular Devices 
microscope IXM XSL every day for 5 days. Having YFP tagged H2B expression only in 
breast cancer cells made it possible to follow the growth of only these cells.  
 
2.2.5.3. RTCA based migration assays 
Migration ability of MSCs treated with media or conditioned media was measured by using 
real time cell analyzer (RTCA) system. To this end 2x104 MSCs were seeded in upper 
chamber of trans-well RTCA plates in 100 µl DMEM-F12 supplemented with 1% FBS. As 
chemoattractant 175 µl of DMEM-F12 supplemented with 10% FBS was used in the lower 
chamber. When cells migrate from the upper chamber of the trans-well towards to the lower 
chamber, they first attached to the bottom part of the trans-well which is covered by 
electrodes. RTCA machine measures the changes in impedance as a result of changing cell 
number and this value is proportional to the number of cells that are attached to the bottom 
part of the trans-well. Migration was monitored real time for 30 hours. 
 
2.2.5.4. Trans-well migration and invasion assay 
4x104 CAF1 cells transfected with control siRNA or siRNA against STC1 were seeded on 
the upper chamber of a 24 well plate format trans-wells in 200 µl DMEM-F12 
supplemented with 1% FBS.  As chemoattractant 500 µl DMEM-F12 supplemented with 
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10% FBS was used in the lower chamber. Migration was stopped by fixing cells using 4% 
PFA after 16 h and crystal violet staining was used to stain the cells fixed on the bottom of 
the trans-wells. Images acquired using a fluorescent microscope.  
 
2.2.6. In vivo experiments 
All in vivo experiments were done under the animal experiment project number of 
133/2015. Isolation and characterization of bone marrow stromal cells by flow cytometry 
analysis were carried out by me. FACS analysis was carried out in Imaging and Cytometry 
Core Facility of DKFZ. Injection of bone marrow stromal cells into mice and in vivo 
imaging were carried out by the group of Dr. Karin Müller-Decker (Tumor Models, 
DKFZ).  
 
2.2.6.1. Isolation of bone marrow stromal cells 
Femur and tibia were collected from wild type 6-8 weeks old BALB/C mice that were 
sacrificed by cervical dislocation. Either wild type BALB/C mice or L2G85.BALB/c mice 
that harbor the CAG-luc-eGFP L2G85 transgene exhibiting widespread expression of 
firefly luciferase directed by the CAG promoter were used for isolating bone marrow 
stromal cells. After removing tissue around the bones, bones were crushed on ice in 
DMEM-F12 supplemented with 10% FBS.  Total bone marrow that was released into the 
media was pelleted by centrifugation in 1600 rpm for 5 min and washed with PBS several 
times. Cell numbers were determined by using a cell counter. Total bone marrow either 
directly cultured in 10 cm cell culture dishes or flow cytometry analysis was performed for 
further characterization. 
 
2.2.6.2. Characterization of bone marrow stromal cells and cell sorting 
Surface staining was carried out with freshly isolated total bone marrow by using  CD31-
APC, CD45-PerCP, Ter119-PerCP, PDGFRa-PeCy7, CD51-PE antibodies as previously 
described (Chapter 2.2.4.1.). CD45, CD31, Ter199 positive cells were gated out to 
eliminate lymphocytes, endothelial cells and erythrocytes respectively. Remaining bone 
marrow stromal cells were further characterized according to their CD51 and PDFGa 
expression and double positive cells were studies as rare mesenchymal stem cell 
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population. Bone marrow stromal cell population cell (CD45-CD31-Ter119-), rare 
mesenchymal stem cell population (CD45-CD31-CD51+PDGFRa+), or bone marrow 
stromal cell population without rare mesenchymal stem cell population (CD45-CD31-
CD51-PDGFRa-) were sorted using FACSAria II in Imaging and Cytometry Core Facility 
of DKFZ.  
 
2.2.6.3. Enrichment of bone marrow stromal cells by magnetic cell sorting  
Magnetic cell sorting (MACS) was used to enrich stromal cells in whole bone marrow 
population. To deplete the blood cells in bone marrow, Lineage Cell Depletion Kit of 
MACS, Miltenyi was used according to manufacturer’s protocol. Another method that 
depletes just lymphocytes was also carried out suing CD45 beads of MACS, Miltenyi 
according to manufacturer’s protocol. However, the highest enrichment was obtained using 
a homemade antibody cocktail. To this end, total bone marrow cells were stained with 
biotinylated antibodies against CD45, CD31 and Ter119 diluted in PBS supplemented with 
2% FBS for 30 min on ice. Afterwards, cells were washed and incubated with Streptavidin 
beads (MACS, Miltenyi) for 15 min on ice and magnetic sorting was carried out according 
to manufacturer’s protocol.  
 
2.2.6.4. Luciferase Assay 
Luciferase activity was measured in bone marrow stromal cells isolated either from wild 
type BALB/C mice or L2G85.BALB/c mice. For this 3x103 cells were seeded in white 96 
well plates. MCF7 cells transfected with a luciferase expressing plasmid was used as 
control. Next day, cells were lysed and treated with the luciferase buffer that contains 
substrate luciferin. Luciferase activity was measured after 3 min incubation using an 
Infinite M200 microplate reader.  
 
2.2.7. Graphical Illustrations 
Unless otherwise mentioned, data are presented as mean ± SD and statistical analyses were 
performed by unpaired two-tailed Student’s t-test using GraphPad Prism Version 7.0. and 
p-values <0.05 were considered statistically significant. p-values <0.05, <0.01 and <0.001 
are indicated with one, two and three asterisks respectively.  
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2.2.8. Statistical analysis 
All graphs were generated using the GraphPad Prism Software and illustrated via 
Inkscape v 0.91 
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3. RESULTS 
3.1. Part 1 
3.1.1 Activation of MSCs with conditioned media treatment or with indirect co-
culture  
To study the effect of breast cancer cells on the activation of MSCs, a triple negative breast 
cancer cell line, namely MDA-MB-231, was selected as the model system. MSCs were 
either co-cultured in an indirect trans-well (TW) setting with MDA-MB-231 cells or treated 
with the conditioned media of these cells for 3 or 7 days to find out the best condition in 
which MSCs become activated. To assess the activation, a collagen gel contraction assay 
was carried out. Figure 3a shows the contraction of MSCs embedded in the collagen matrix 
in different conditions that was quantified by measuring the gel area (Figure 3b). Only after 
conditioned media treatment for 7 days, MSCs were found to be contracting more than the 
control cells. The TW setting, in which MSCs were either co-cultured with MDA-MB-231 
cells or media, did not induce any difference in the contraction ability of the cells, even 
after seven days. 
 
 
Figure 3 Effect of CM treatment or TW co-culture on the contractility of MSCs.  
a. Collagen gel contraction assay with MSCs either treated with media (M) or conditioned media 
(CM) for 3 or 7 days (d) or co-cultured with MDA-MB-231 cells in a trans-well (TW_231) format 
or cultured with media (TW_M) for 3 or 7 days b. Quantification of collagen gel area showing the 
fold changes relative to respective media samples and the values are presented as mean ± SD of 3 
technical replicates.  
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Another way to check the activation of MSCs is to measure the changes in the expression 
levels of activation markers such as SMA and FAP. Indeed, these markers were detected 
at the protein level upon treatment with either conditioned media or in the TW co-culture 
setting (Figure 4). While TW co-culture increased the expression of FAP after 7 days, 
SMA levels went down both after 3 and 7 days (Figure 4a). In the conditioned media 
setting, however, FAP was already upregulated after 7 days of treatment and remained up 
after 14 days. SMA expression was upregulated after 14 days of conditioned media 
treatment that might imply a gradual increase in the activation of MSC. In conclusion, the 
conditioned media setting activated the MSC more than the TW setting did. Therefore, I 
decided to use the conditioned media of MDA-MB-231 cells to activate MSCs. It should 
be noted at this point that even the media-treated MSC population had cells expressing 
FAP and SMA demonstrating that these cells already had a baseline activation. 
 
Figure 4 Effect of CM treatment or TW co-culture on the expression of αSMA and FAP Flow 
cytometry analysis of MSCs either a. co-cultured with MDA-MB-231 cells in a trans-well 
(TW_231) format or b. treated with media M or CM for 7 or 14 days. The graphs demonstrate the 
percentage of positive cells for FAP or SMA expression (a-b) and the values are presented as 
mean ± SD of 3 biological replicates (b). * p< 0.05, ns: not significant 
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3.1.2. Activation of MSCs with prolonged CM treatment 
To understand whether an extended treatment with conditioned media would have an 
additive effect on the activation of MSCs, conditioned media treatment was continued to 
21 days. Then, a collagen gel contraction assay was performed to measure the activity of 
the cells. An increase in the contractility of MSCs was observed both at 7 and 14 days of 
treatment with conditioned media (Figure 5a-b). However, this difference was not 
significant after 21 days of conditioned media treatment. Hence, I chose to continue 
experiments using conditioned media treatment taking the 7 and 14 days time points.   
 
Figure 5 Effect of prolonged CM treatment on the contractility of MSCs Collagen gel 
contraction assay with MSCs either treated with M or CM for 3, 7 or 21 days b. Quantification of 
collagen gel area showing the fold changes relative to respective media samples and the values are 
presented as mean ± SD of 3 technical replicates. * p< 0.05, ns: not significant 
 
3.1.3. Expression of cytokines upon CM treatment 
Upon activation, fibroblasts start secreting various factors, including cytokines and 
chemokines. Hence, I next wanted to know which cytokines were regulated in my 
experimental system. To this end, MSCs were treated with conditioned media from MDA-
MB-231 cells for 7 and 14 days, and the expression of selected cytokines and other relevant 
genes was tested. Indeed, the expression of IL6, IL8, CCL2, CCL5 and MCP1 expression 
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was upregulated at mRNA level both after 7 and 14 days. Out of two MMPs that were 
measured, while MMP1 was upregulated, the expression of MMP2 did not change (Figure 
6). 
 
 
Figure 6 Effect of CM treatment on the expression of various cytokines Expression analysis of 
various cytokines in MSCs treated with media M or CM for 7 or 14 days using TaqMan qRT-PCR. 
The graph shows the fold changes relative to 7d M sample and the values are presented as mean ± 
SD of 3 biological replicates. 
 
3.1.4. Phenotypic changes in MSCs upon activation with CM 
Next, I investigated possible phenotypic changes that can be induced in MSCs with the CM 
treatment. Therefore, changes in the proliferation and migration ability of the cells were 
measured as increased proliferation and migration are associated with activated fibroblasts 
and CAFs. For this, a proliferation assay by nuclei count and a real time migration assay in 
trans-well format were performed. There was no change in the number of cells counted 
upon conditioned media treatment that might indicate the lack of effect of conditioned 
media on the doubling time of MSCs (Figure 7a). However, an increase was observed in 
the number of migrating cells only after 14 days of conditioned media treatment which is 
in line with the probable gradual activation of MSCs upon 7 and 14 days of treatment 
(Figure 7).   
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Figure 7 Effect of CM treatment on proliferation and migration a. MSCs were treated with 
media M or CM for 7 or 14 days and the changes in proliferation was measured by counting nuclei. 
The graphs demonstrate the fold changes in the growth of the cells relative to M control and the 
values are presented as mean ± SD of 6 technical replicates. b. TW migration assay using RTCA. 
Data for each time point is presented as mean ± SD of 4 technical replicates.  
 
3.1.5. Impact of activated MSCs on cancer cell growth 
The effect of CAFs on the tumor progression is well known (Kalluri, 2016). In order to 
investigate the influence of MSCs on the cancer cell growth, I directly co-cultured MSCs 
with various breast cancer cell lines and measured the changes in their growth. Figure 8 
and 9 show the growth curves of the cancer cell lines that were co-cultured with media or 
conditioned media treated MSCs or mono-cultured for 7 (Figure 8) or 14 days (Figure 9). 
While growth of the two triple negative breast cancer cell lines, MDA-MB-231 and 
HCC1937 was not affected by the presence of MSCs, another triple negative cell line, 
namely HS578T, proliferated more in the co-culture setting with a higher proliferation with 
CM treated MSCs compared to media treated MSCs. The luminal cell lines, MCF7 and 
T47D also proliferated more in the co-culture with MSCs but there were no additive effects 
coming from the CM treated MSCs.  
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Figure 8 Effect of 7 days CM treated MSCs on the growth of breast cancer cell lines Breast 
cancer cell lines were co-cultured with 7 day M treated (CC-M) or CM treated (CC-CM) MSCs or 
mono-cultured (MC). The graphs demonstrate the growth of breast cancer cell lines as fold change 
relative to mono culture over time and the values are presented as mean ± SD of 2 biological 
replicates with 6 technical replicates each. * p< 0.05, ** p< 0.01, *** p< 0.001 
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Figure 9 Effect of 14 days CM treated MSCs on the growth of breast cancer cell lines Breast 
cancer cell lines co-cultured with 14 day M treated (CC-M) or CM treated (CC-CM) MSCs or 
mono-cultured (MC). The graphs demonstrate the growth of breast cancer cell lines as fold change 
relative to mono culture over time and the values are presented as mean ± SD of 2 biological 
replicates with 6 technical replicates each. * p< 0.05, ** p< 0.01, *** p< 0.001 
 
Next, in order to understand the mechanism behind this differential impact of MSCs on the 
growth of different breast cancer cell lines, the same experiment was repeated this time 
using the conditioned media of media or conditioned media treated MSCs to understand 
whether the observed effects were due to direct cell-cell contact or paracrine factors (Figure 
10 and 11). Although HS578T cells grew more when they were exposed to the conditioned 
media of MSCs compared to the mono-culture control, there were no growth difference 
between the HS578T cells treated with the conditioned media of media and conditioned 
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media of conditioned media treated MSCs. Therefore, it might be concluded that direct 
cell-cell contact is required for the increased proliferation when HS578T cell were co-
cultured with the conditioned media treated MSCs. Moreover, there was a small difference 
in the proliferation of MDA-MB-231 cells growing in mono-culture or treated with the 
conditioned media of MSCs that was not observed with the direct co-culture setup. This 
difference might be explained by the increased abundance and accumulation of secreted 
proteins in the conditioned media compared to more diluted co-culture condition.  
All in all, although it was observed that MSCs, in general, have an impact on the growth 
of cancer cell lines, only HS578T cells grew better in the co-culture with the conditioned 
media treated and activated MSCs.  
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Figure 10 Effect of conditioned media of 7 days CM treated MSCs on the growth of breast 
cancer cell lines Breast cancer cell lines are treated with conditioned media of 7 day M treated 
(CM-M) or CM treated (CM-CM) MSCs or mono-cultured (MC). The graphs demonstrate the 
growth of breast cancer cell lines as fold change relative to mono culture over time and the values 
are presented as mean ± SD of 2 biological replicates with 6 technical replicates each. * p< 0.05, 
** p< 0.01, *** p< 0.001 
 
 
Figure 11 Effect of conditioned media of 14 days CM treated MSCs on the growth of breast 
cancer cell lines Breast cancer cell lines are treated with conditioned media of 14 day M treated 
(CM-M) or CM treated (CM-CM) MSCs or mono-cultured (MC). The graphs demonstrate the 
growth of breast cancer cell lines as fold change relative to mono culture over time and the values 
are presented as mean ± SD of 2 biological replicates with 6 technical replicates each. * p< 0.05, 
** p< 0.01, *** p< 0.001 
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3.1.6. Differential gene expression and methylation analysis upon CM treatment 
Next, I investigated whether epigenetic regulation has a role in the activation of fibroblasts. 
I hypothesized that changes in DNA methylation of MSCs might explain how cells get this 
activated fibroblast phenotype and might also contribute to the regulation of cytokines and 
other genes being upregulated during activation. Therefore, to determine the alterations in 
DNA methylation pattern upon conditioned media treatment, differentially methylated 
CpGs (probes) were determined using EPIC methylation array. RNA sequencing was also 
performed to assess whether an observed change in DNA methylation affects also the 
expression of a selected gene. Initial analysis of methylation data demonstrated that there 
were small differences (up to approximately 20%) in DNA methylation upon conditioned 
media treatment (Figure 12a). After 7 days of treatment with conditioned media, there were 
just very few CpGs differentially methylated while that number increased after 14 days of 
treatment (Figure 12b).  
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Figure 12 Differential methylation analysis of CM treated MSCs vs. control MSCs a. 
Comparison of methylation status of each probe in media and conditioned media treated MSCs. b. 
Volcano plots are depicted with the beta value of each probe relative to media treatment and the –
log10p-value of the difference in methylation levels.  
 
According to the differential gene expression analysis, the numbers of differentially 
expressed genes were similar for 7 day and 14 day of conditioned media treatment. 
Moreover, in most of the cases differential expression pattern for a gene was similar in 7 
and 14 days samples meaning that if a gene was upregulated after 7 days of conditioned 
media treatment, it was still upregulated in the 14 day samples (Figure 13).   
 
 
Figure 13 Differential gene expression analysis of CM treated MSCs. The graphs are depicted 
with log2-fold change and mean of normalized counts and they represent the distribution of 
magnitude of fold changes relative to mean expression for 7 (a) and 14 (b) day samples. 
 
To find out common genes that are both differentially expressed and methylated an 
integrated analysis were carried out. Having at least one differentially regulated CpG in the 
promoter region (covering 1500 bp upstream of the transcription start site) or in the gene 
body was set as criterion to select a gene as differentially methylated. CpGs mapping to 
enhancer regions or to intergenic sequences were not regarded. This identified 273 genes 
that were both differentially methylated and differentially expressed after 7 days of 
treatment (Figure 14, 7d). For 14 days treatments, this number was 617 genes (Figure 14, 
14d). Although several single CpGs were detected as differentially methylated, for most of 
the genes, there were no differentially methylated regions (two or more neighboring CpG 
differentially methylated at the same time) in which group of CpGs were differentially 
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methylated together. This observation would indicate that the methylation status of a single 
CpG located in the promoter region of a gene might not be playing a role in its expression. 
Therefore, I decided to focus on the RNA seq data to find out differentially expressed genes 
that might explain the activation phenotype of MSCs upon conditioned media treatment 
regardless of their methylation status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Correlation of DNA methylation and RNA sequencing. The VENN diagrams 
demonstrate the number of differentially methylated positions (DMP) detected by 850k EPIC 
methylation array and differentially expressed genes (DEG) detected by RNA sequencing upon CM 
treatment for 7 or 14 days. Common genes between DMPs and DEGs are depicted with green 
arrows.  
Next, using RNA sequencing data, differentially regulated pathways upon conditioned 
media treatment were investigated. For this, KEGG enrichment analysis was performed 
using genes that are differentially expressed with a log2-fold change greater than 2. Most 
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of the identified pathways that are significantly regulated (p<0.05 after correction for 
multiple testing) were associated with inflammation (Figure 15). TNFα signaling and 
chemokine signaling pathways, cytokine-cytokine receptor interaction and the NF-κB 
signaling pathway were among the significantly regulated pathways both after 7 and 14 
days of treatment. This observation might explain the upregulation of gene expression of 
various cytokines with the conditioned media treatment (Figure 6) and might indicate that 
conditioned media treatment induces the activation of inflammatory pathways that have a 
potential to also change the secretome profile of activated MSCs. 
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Figure 15 Pathway enrichment analysis. KEGG pathway enrichment analysis for differentially 
expressed genes upon 7 (a) or 14 (b) days of CM treatment. Raw and corrected p-values are shown 
on a -log10 scale. 
 
3.1.7. Secretome analysis of activated MSCs 
Detection of inflammatory pathways among the top differentially regulated pathways might suggest 
changes in the secretome of MSCs upon conditioned media treatment. To address this, proteomic 
analysis was performed to detect differentially secreted proteins in the activated MSCs in an 
unbiased approach. For this, after treatment with conditioned media for 7 or 14 days, cells 
were labelled with AHA and SILAC and subsequent analysis was carried out with LC 
tandem-MS to detect both differentially secreted and intracellular proteins. This method 
allows specific identification and quantification of newly synthesized proteins of labelled 
cells to distinguish these from proteins that had been present in the conditioned medium. 
Figure 16 shows the results of the proteomic analysis. Intracellular proteins were measured 
using cell pellets. For 7 days of conditioned media treatment, out of 882 different protein 
detected, 23 of them were differentially expressed. 
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Figure 16 Mass spectrometry analysis of differentially regulated proteins upon 7 or 14 days 
of CM treatment. Volcano plots depict fold changes for each detected protein and the –log10 p 
value for intracellular (a) and extracellular proteins (b). Changed: log2 fold change more than 0.8 
with a p value less than 0.05. ns: no significant change  
 
In 14 day samples, 1243 protein was detected and 52 of them were differentially expressed. 
Extracellular (secreted) proteins were measured using supernatants of MSCs upon 
labelling. For 7 days of conditioned media treatment, out of 82 distinct proteins detected, 
20 were differentially expressed. In 14 day samples, 99 protein were detected and 52 of 
these were differentially expressed. In the intracellular and extracellular proteins which 
were found to be differentially expressed, there were several having been previously 
associated with activated fibroblasts or CAFs such as αSMA, GAS6, TGM2, IL6, VCAM1, 
MMP1 thus validating the approach. The analysis to detect differentially expressed proteins 
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requires at least two peptides to be detected in both SILAC channels in order to build a 
ratio (proteins shown in Figure 23). However, peptides from proteins close to the limit of 
detection or which are highly secreted in one of the two experimental conditions can 
sometimes fail to build such a ratio, for instance when peptides are predominantly detected 
on only one of two SILAC channels. To capture the dynamics of these proteins as well, a 
(pseudo)-ratio was built from the summed SILAC channels of all the detected peptides 
regardless whether both forms of a peptide were present giving an indication in which 
condition the protein is predominantly secreted (Table 7). If peptides were only detected in 
one of the two conditions then this condition is indicated. 
 
Table 7 Analysis of extracellular proteins predominantly detected in one SILAC channel. 
Extracellular proteins altered upon conditioned media treatment for 7 or 14 days. CM: conditioned 
media channel M: Media channel nd: not detected 
 
Extracellular 
proteins log2 fold change CM/M 
 Gene 
name 
Replicate 1 Replicate 2 Replicate 3 
7d 
CXCL1 7,2 CM 7,7 
STC1 2,9 5,2 6,7 
MMP3 3,3 5,7 4,8 
POSTN 1,9 1,6 2,5 
KANK1 4,7 5,9 4,2 
SOD3 2,5 3,7 2,2 
STC2 nd 1,2 1,2 
14d 
STC1 CM 3,4 CM 
MMP3 5,6 2,1 4,9 
STC2 1,2 nd 1,1 
IGFBP1 M -2,9 -1,4 
PLAU -1,3 -1,5 -1,9 
 
3.2.8. Target selection from RNA seq and secretome data 
To select targets that might have a role in the activation of MSCs, I focused on the 
upregulated genes. Figure 17 demonstrates common genes that are found to be upregulated 
both at RNA and protein levels.  
 
Dissertation   Neşe Erdem 
 
 
85 
 
Figure 17 Upregulated genes and proteins upon CM treatment. The graphs represent log2-fold 
changes of upregulated genes detected both in RNA sequencing and respective proteins in mass 
spectrometry.  
 
MMP1, MMP3, IL6 and CXCL1 are among the top 5 proteins that were upregulated after 
7 days of conditioned media treatment and are all well-established CAF-secreted proteins 
(Kalluri, 2016). The other is STC1. This protein is not expressed in MSCs, however, its 
expression was stimulated by treatment with conditioned media from MDA-MB-231 tumor 
cells and could be detected also after 14 days of treatment with the conditioned media, both 
at mRNA and protein levels (Figure 17). Stanniocalcin 1 (STC1) is a secreted protein that 
has been shown to have inhibitory effects on calcium uptake in human cells (Xiang et al., 
2016). Although the mechanism is not well established, STC1 has been also associated 
with CAFs and implicated as a CAF-secreted protein that is involved in metastasis of 
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colorectal (Peña et al., 2013) and therapy resistance in breast cancer (Roswall et al., 2018). 
STC1 secreted by MSCs has been also linked to fibrosis and shown to decrease collagen 
deposition (Ono et al., 2015). However, whether STC1 has an active role in the activation 
of fibroblasts or if its expression is a bystander effect in MSCs is still an open research 
question. Therefore, STC1 was chosen for further studies to better understand the 
mechanism of its upregulation and involvement in the activation of fibroblasts. 
Upregulation of STC1 in conditioned media-treated MSCs was validated both at mRNA 
and protein levels by real time PCR and ELISA respectively (Figure 18). Also, 
upregulation with conditioned media at mRNA level was confirmed in MSCs isolated from 
four other different donors (Figure 19).  
 
 
Figure 18 Validation of STC1 upregulation upon CM treatment. a. Expression analysis of 
STC1 in MSCs treated with media M or CM for 7 or 14 days using TaqMan qRT-PCR. The graph 
shows the fold changes relative to 7d M sample and the values are presented as mean ± SD of 3 
biological replicates b. ELISA analysis of STC1 using supernatants of MSCs treated with media M 
or CM for 7 or 14 days. The graph shows amount of STC1 in the supernatants and the values are 
presented as mean ± SD of 3 biological replicates. BDL: Below detection limit 
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Figure 19 Analysis of STC1 expression in MSCs isolated from different donors. Expression 
analysis of STC1 in MSCs treated with media M or CM for 7 or 14 days using TaqMan qRT-PCR. 
The graph shows the fold changes relative to 7d M sample and the values are presented as mean ± 
SD of 3 biological replicates. D2-5: Donor 2-5. ** p< 0.01 
 
3.2.9 Mechanism of STC1 upregulation upon conditioned media treatment in MSCs 
Next, I wanted to investigate mechanisms behind the observed upregulation of STC1 and 
hypothesized that NF-κB signaling might play a role there. In pathway enrichment analysis 
(Figure 15) NF-κB pathway was among the most significantly differentially regulated 
pathways upon activation of MSCs with conditioned media treatment. Additionally, I 
focused on transcription factors that have predicted binding sites in the promoter region of 
the STC1 gene. To understand the possible involvement of different transcription factors 
in the upregulation of STC1, MSCs were transfected with siRNAs targeting these 
transcription factors to down-regulate their expression. Afterwards, MSCs were treated 
with conditioned media of MDA-MB-231 cells for 24 hours and expression of STC1 was 
determined at the mRNA level (Figure 20). In control conditions, even 24 hours treatment 
with conditioned media was sufficient to upregulate STC1 expression. Moreover, out of 
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five transcription factors tested, downregulation of only RELA and RELB abrogated the 
upregulation of STC1 induced by conditioned media treatment thus indicating the role of 
NF-κB signaling in the regulation of transcription of the STC1 gene.  
 
Figure 20 Analysis of STC1 expression in MSCs isolated from different donors Expression 
analysis of STC1 in MSCs transfected with siRNAs targeting genes and treated with media M or 
CM for 24h using TaqMan qRT-PCR. The graph shows the fold changes relative to media treated 
control transfection (siCTRL_M) sample and the values are presented as mean ± SD of 3 biological 
replicates. * p< 0.05 
 
3.2.10. Role of STC1 in the activation of conditioned media treated MSCs 
Having shown the regulation of STC1 expression at the mRNA level, STC1 was down-
regulated (RNAi) in MSCs treated with media or conditioned media to investigate the 
possible involvement of STC1 in the activation of MSCs. While downregulation of STC1 
with a specific siRNA was efficient at the protein level, this was ~80% at the RNA level 
(Figure 21). 
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Figure 21 Analysis of STC1 expression upon siRNA knock-down. a. Expression analysis of 
STC1 in MSCs transfected with siCTRL or siSTC1 and treated with media M or CM for 7 or 14 
days using TaqMan qRT-PCR. The graphs show the fold changes relative to media treated control 
transfection (siCTRL_M) and the values are presented as mean ± SD of 3 biological replicates b. 
ELISA analysis of STC1 using supernatants of MSCs transfected with siCTRL or siSTC1 and 
treated with media M or CM for 7 or 14 days. The graphs show amount of STC1 in the supernatants 
and the values are presented as mean ± SD of 3 biological replicates BDL: Below detection limit. 
* p< 0.05, ** p< 0.01, *** p< 0.001 
  
Having confirmed that RNAi of STC1 indeed down-regulated the gene both at mRNA and 
protein levels, I wanted to check the effect of this down-regulation on the contraction 
ability of MSCs. To this end, STC1 was knocked down in MSCs, treated the cells with and 
without conditioned media for 7 (Figure 22a, b) and 14 (Figure 22c, d) days, and quantified 
the cells’ contraction ability of MSCs.  
 
No literature??? 
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Figure 22 Effect of STC1 knock-down on the contractility of activated MSCs. a-b Collagen gel 
contraction assay with MSCs transfected with siCTRL or siSTC1 and treated with media M or CM 
for 7 (a) or 14 (c) days. b-d The graphs represent fold changes in gel areas relative to siCTRL_M 
samples. Values are presented as mean ± SD of 3 biological replicates. * p< 0.05, ** p< 0.01, *** 
p< 0.001, ns: not significant 
 
Next, effects of STC1 knock-down on the expression of CAF markers in MSCs treated 
with conditioned media were explored (Figure 23). Down-regulation of STC1 in cells 
treated with normal medium for 7 days caused down-regulation in FAP as well as αSMA 
expression. There, the increase in the levels of FAP was reduced in cells with 
downregulated STC1 treated with conditioned media, while the slight increase in αSMA 
expression observed in the control conditions was abrogated in knock-down cells. In 
contrast, at 14 days, for FAP expression, the initial strong difference between control and 
STC1 know-down cells treated with conditioned media were not seen anymore, while the 
reduced expression of SMA expression upon STC1 knock-down was still visible. Hence, 
the effect of STC1 seems to be temporal for FAP expression, however, sustained for 
SMA. 
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Figure 23 Effect of STC1 knock-down on the expression of SMA and FAP in activated MSC 
Flow cytometry analysis of MSCs transfected with siCTRL or siSTC1 and treated with media M 
or CM for 7 or 14 days. The graphs demonstrate the percentage of positive cells for FAP or SMA 
expression and the values are presented as mean ± SD of 2 biological replicates (except for FAP 
14d).  
 
3.2.11. Role of STC1 in the activation of CAFs 
After having shown that STC1 indeed has an effect on the activation of MSCs, next, I 
analyzed the impact pf STC1 knock-down on already activated CAFs. For this purpose, I 
determined the expression levels of STC1 in CAFs isolated from breast tumor samples of 
three different donors (Figure 24). CAF1 and CAF2 were chosen for further validation 
because they had the highest expression of STC1 among the CAFs that were tested. 
However, it is important to note that although the level STC1 expression in CAF1 and 
CAF2 cells was found higher than in MSCs after treatment with media, their expression 
did not reach the high levels that were measured in MSCs having been treated with 
conditioned media from tumor cells. Interestingly, STC1 was expressed at high levels also 
in most tumor cell lines, including MDA-MB-231. 
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Figure 24 Expression of STC1 in MSCs and CAFs. Expression analysis of STC1 in MSCs, in 
primary CAFs isolated from different donors and in several breast cancer cell lines using TaqMan 
qRT-PCR. The graph shows the fold changes relative to media treated control MSC sample and the 
values are presented as mean ± SD of 3 biological replicates.  
 
In order to understand the effect of STC1 on the activation of selected CAFs a collagen gel 
contraction assay was performed upon siRNA knock-down of STC1. Interestingly, the two 
CAF cell lines showed contradictory results in this assay. While knock-down of STC1 
resulted in inhibition of contraction in CAF1 cells, this was not observed in CAF2 cells 
(Figure 25). 
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Figure 25 Effect of STC1 knock-down on the contractility of CAFs. a-b Collagen gel 
contraction assay with CAF1 (a) and CAF2 (b) transfected with siCTRL or siSTC1 b-d The graphs 
represent the fold changes in gel area relative to siCTRL samples and the values are presented as 
mean ± SD of 3 biological replicates ** p< 0.01, ns: not significant 
 
To identify potential causes of the different phenotypes having been observed with CAF1 
and CAF2 cells, I investigated whether knock-down of STC1 would also have an impact 
on the expression of CAF markers in these cells (Figure 26). While the number of CAF1 
cells expressing SMA was reduced upon STC1 knock-down, this effect was not seen in 
CAF2 cells. However, the fraction of SMA-positive cells was higher in the CAF1 than in 
the CAF2 cell populations at baseline conditions. Similar to SMA, also FAP was 
expressed in a smaller percentage of CAF2 cells compared to CAF1. Hence, there seem to 
be differences in the level of activation between the two CAF entities. Therefore, CAF1 
was chosen for further experiments due to its higher contractility and higher expression of 
FAP and SMA. 
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Figure 26 Effect of STC1 knock-down on the expression of SMA and FAP in CAFs. Flow 
cytometry analysis of CAF1 and CAF2 cells transfected with siCTRL or siSTC1. The graphs 
demonstrate the percentage of positive cells for FAP or SMA expression and the values are 
presented as mean ± SD of 3 biological replicates (CAF1). 
 
Activated CAFs have increased migration and invasion abilities compared to naïve 
fibroblasts.  Therefore, in order to determine if STC1 would also have an impact on these 
activation phenotypes, trans-well migration and invasion assays were carried out. Indeed 
knock-down of STC1 caused a decrease in the number of migrating or invading CAF1 cells 
(Figure 27).  
 
 
 
Figure 27 Effect of STC1 knock-down on migration and invasion of CAFs. Trans-well 
migration and invasion assays of CAF1 cells transfected with siCTRL or siSTC1.                                                                
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3.2.12. Role of STC1 in the impact of CAFs on cancer cell growth 
The effect of CAFs on tumor progression is well known (Kalluri, 2016). In order to 
investigate the influence of CAFs with down-regulated STC1 expression on the cancer cell 
growth, I directly co-cultured CAF1 cells transfected with control siRNA or siRNA against 
STC1 with various breast cancer cell lines and measured the changes in their growth. 
Figure 28 is showing the growth curves of cancer cell lines during 4 days of co-culture or 
mono-culture. While the presence of CAFs did not affect the growth of MDA-MB-231 
cells, all the other cell lines grew better in the presence of CAF1 cells. However, no 
difference was observed when cancer cells were co-cultured with CAF1 cells transfected 
with control siRNA or siRNA targeting STC1 indicating that STC1 secreted by CAFs does 
not have any role on the growth of cancer cells.  
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Figure 28 Effect of CAF1 cells on the growth of breast cancer cell lines Breast cancer cell lines 
were co-cultured with CAF1 cell transfected with siCTRL (CC-siCTRL) or transfected with 
siSTC1 (CC-siSTC1) or mono-cultured (MC). The graphs demonstrate the growth of breast cancer 
cell lines as fold change relative to mono culture over time and are presented as mean ± SD of of 2 
biological replicates with 6 technical replicates each. * p< 0.05, ** p< 0.01, *** p< 0.001 
 
3.2.13. Deconvolution of siSTC1 pool 
Deconvolution of the 4 siRNAs of the STC1 pool demonstrated that all siRNAs decreased 
STC1 expression at the mRNA level (Figure 29d). However, their effects on the contraction 
ability of CAF1 cells and ACTA2 expression were different (Figure 29a and d). While 
siRNA numbers 1, 2 and 3 had similar effects as the pool, siRNA number 4 did neither 
affect the contraction nor ACTA2 expression. I also tested the effect of siRNAs on cell 
growth and demonstrated that siRNA number 3 slightly but insignificantly, reduced growth 
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of CAF1 cells (Figure 29c). Since siRNA number 1 both downregulated ACTA2 and 
inhibited the contraction, this siRNA was chosen for use in further experiments.  
 
 
 
Figure 29 Deconvolution of siSTC1 pool a. Collagen gel contraction assay with CAF1 cells 
transfected with siCTRL or four different siRNAs for STC1 that are in siSTC1 pool. b. The graph 
represents the fold changes in gel area relative to siCTRL samples and the values are presented as 
mean ± SD of 3 technical replicates. c. Nuclei count of CAF1 cells. The graph represents the fold 
changes in growth relative to siCTRL samples and the values are presented as mean ± SD of 6 
technical replicates. d. Expression analysis of STC1 and ACTA2 in CAFs. The graph shows the 
fold changes relative to media treated relative to siCTRL samples and the values are presented as 
mean ± SD of 3 biological replicates. 
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3.2.14 Pathway analysis upon STC1 knock-down in CAF1 cells 
The results described above suggested that STC1 might have a role in the activation of 
fibroblasts. To validate this hypothesis, it was required to identify pathways that are 
regulated by knock-down of STC1 in CAF1 cells. This should help identifying mechanisms 
by which STC1 impacts on contraction, SMA expression, migration and invasion. For 
this, proteomic analysis by reverse phase protein array (RPPA) was performed to identify 
pathways that are differentially activated upon STC1 knock-down. Out of several pathways 
that were analyzed (MAPK, Akt/mTOR, PI3K, NOTCH, Wnt), NOTCH signaling and Wnt 
signaling were the most changed ones (Figure 30). The figure shows heat maps for the 
changes in the expression of proteins belonging to these two signaling pathways. Red stars 
indicate statistically significant changes. For Notch signaling, two receptors of the 
pathway, namely, NOTCH2 and NOTCH3 were found to be downregulated upon knock-
down of STC1. Moreover, for Wnt signaling, a down-regulation on β-catenin and phospho-
β-catenin was observed. 
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Figure 30 Effect of STC1 knock-down on different pathways Heat map of all analyzed proteins 
(Upper panel). RPPA results of NOTCH and Wnt signaling pathways. Heat maps shows the signal 
intensities of the proteins belonging to Wnt and NOTCH signaling in CAF1 cells transfected with 
siCTRL or siSTC1. Significantly changing proteins are labeled with red stars (p<0.05). The graphs 
show the signal intensities for specific proteins and the values are presented as mean ± SD of 3 
biological replicates. * p< 0.05, ** p< 0.01 
 
3.2.15. STC1 expression in patient 
After having demonstrated the possible role of STC1 in the activation of fibroblasts in vitro, 
in order to investigate the relevance of this finding in breast cancer patients, publicly 
available datasets were analyzed for the expression of STC1 in human tumors. First, I 
checked the expression of STC1 in different molecular subtypes of breast cancer using the 
TCGA dataset. This contains RNA sequencing data of tumors from 1200 individual 
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patients. No difference in the expression of STC1 was observed among the different 
subtypes (Figure 31). Since TCGA data set has information about the whole tumor without 
making a distinction between tumor and stromal cells, I decided to analyze microarray 
datasets that were obtained using RNA samples from stroma or epithelium of patient tumor 
samples obtained with laser capture microdissection of tissues. For this, four publicly 
available microarray datasets were analyzed (GSE14548, GSE35019, GSE9014, 
GSE5847). STC1 expression was indeed found elevated in the stroma of ductal carcinoma 
in situ (DCIS) compared to the stroma of normal breast tissue and epithelium of DCIS in 
the GSE14548 dataset (Figure 31b). However, in the case of, invasive carcinoma there is 
no significant difference in the expression of STC1 between the stroma and epithelium 
(Figure 31b). No significant differences in STC1 expression between different parts of 
tumors were obvious in another data set covering of a similar type of samples (Figure 31c). 
I checked the expression STC1 in another two data sets and compared its expression 
between normal breast tissue stroma and tumor stroma (GSE9014) or between tumor 
stroma and tumor epithelium (GSE5847).  I found data tumor stroma has higher expression 
of STC1 compared to the normal breast tissue stroma (Figure 31d). However, there was no 
difference in the expression of STC1 between tumor stroma and tumor epithelium (Figure 
31e). Hence, the results from patient data sets were inconclusive. 
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Figure 31 STC1 expression in breast cancer patients a. STC1 mRNA expression analysis of the 
TCGA dataset comparing the different molecular subtypes of breast cancer b-c-d-e STC1 mRNA 
expression analysis of different microarray datasets 
 
Moreover, since it was observed that with the down-regulation of STC1 expression, ACTA2 
expression was also going down, the correlation between the expression of these two genes 
in the stroma part of tumors was determined. In the two datasets that were analyzed, there 
was a significant correlation between ACTA2 and STC1 (Figure 32).  
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Figure 32 Correlation between STC1 and ACTA2 expression in patients Correlation analysis 
of stromal STC1 with ACTA2 gene expression of two different data sets. Correlation coefficient (r) 
was calculated using Pearson correlation. 
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3.2. Part 2 
3.2.1. Characterization of bone marrow stromal cells 
To study the recruitment of different stromal cell populations from the bone marrow to the 
tumor site, bone marrow cells were isolated from BALB/C mice and characterized either 
immediately after isolation or after keeping them in culture for 28 days. Figure 33a shows 
the bright field images of bone marrow cells immediately after isolation and after 7 or 28 
days in culture. While there were still floating hematopoietic cells present after 7 days in 
culture, after 28 days in culture, the most abundant population was adherent fibroblast like 
stromal cells. To quantify the percentage of bone marrow stromal cells (CD45-CD31-), 
hematopoietic cells (CD45+), endothelial cells (CD31+) and rare mesenchymal stem cell 
(CD45-CD31-CD51+PDGFRa+) population, flow cytometry analysis was performed. 
Figure 33b demonstrates the dot plots of flow cytometry analysis of freshly isolated total 
bone marrow and bone marrow stromal cells cultured for 28 days. Directly after isolation, 
stromal cells constituted about 20% of bone marrow cells while the rare CD51 and 
PDGFRα double positive stem cell population was just 0.01% (Figure 33c). The percentage 
of mesenchymal stem cells stayed the same in the whole population of cultured cells, 
despite the stromal population was enriched over non-adherent hematopoietic cells that 
were efficiently removed after several medium changes. Therefore, I decided not to culture 
the cells in the bone marrow isolates but instead to either sort the whole bone marrow 
stromal population or only mesenchymal stem cells by fluorescence-activated cell sorting 
(FACS) directly after isolation of the bone marrow.  
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Figure 33 Characterization of bone marrow cells a. Bright field images of total bone marrow, 7 
day cultured bone marrow and 28 day cultured bone marrow b. Flow cytometry analysis of total 
bone marrow and 28 days cultured bone marrow c. Graphical representation of flow cytometry 
data. BM: bone marrow 
 
Since the rare mesenchymal stem cells represent a very small population, the non-stromal 
part of the bone marrow had to be depleted before cell sorting to reduce the time of sorting 
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and to increase efficiency. Therefore, different strategies were tested to deplete the non-
stromal part of the bone marrow using magnetic cell sorting (MACS). Out of three different 
techniques (Figure 34a), depletion of CD45+Ter119+CD31+ cells resulted in the highest 
enrichment of the stromal cell population with almost 60% of the cells being CD45-CD31- 
Ter119- (Figure 34b).  
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Figure 34 Enrichment of stromal cells by MACS a. Lineage depletion with lineage depletion kit 
of MACS Miltenyi, depletion of CD45 positive cells with CD45 beads from MACS Miltenyi, 
depletion of CD45+Ter119+CD31+ cells with homemade antibody cocktail b. Graphical 
representation of flow cytometry data. 
 
3.2.2. Injection of different populations of bone marrow stromal cells into mice 
After having isolated and characterized stromal cells from the bone marrow, the next step 
was to inject those cells into mice. In order to be able to trace the cells after injection, bone 
marrow stromal cells were isolated from mice that have luciferase expression in every 
tissue. To first test whether it was possible to monitor bone marrow stromal cells in vivo, 
cells from the whole bone marrow stromal population, mesenchymal stem cells, or bone 
marrow stromal cells having been depleted of mesenchymal stem cells were injected 
subcutaneously into wild type BALB/C mice. Figure 35 is showing images taken using 
IVIS, an in vivo imaging system, over three weeks after the injection. No signal above the 
threshold was detected 
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Figure 35 In vivo imaging of subcutaneous injection of bone marrow stromal cells Injection of 
different bone marrow stromal cell populations 1. CD45-Ter119-CD31-CD51+PDGFRa+ 2. CD45-
Ter119-CD31-CD51-PDGFRa- 3. CD45-Ter119-CD31-. 
 
To make sure that bone marrow stromal cells do not lose luciferase expression upon 
isolation, luciferase activity of freshly isolated bone marrow cells was determined using a 
luciferase assay. Figure 36 shows the luciferase activity of bone marrow stromal cells 
isolated from a wild type BALB/C (WT BALBc) mouse or three different luciferase 
reporter mice (L2G85 BALBc). While no luciferase activity was detected in bone marrow 
stromal cells of wild type mice, bone marrow stromal cells of the luciferase reporter mice 
had strong luciferase activity comparable with a breast cancer cell line in which the 
luciferase gene is stably overexpressed (MCF7_luc).    
 
 
Figure 36 Detection of luciferase activity of bone marrow stromal cells In vitro luciferase assay 
of freshly isolated bone marrow stromal cells of different mice. The graph shows luciferase activity 
and the values are presented as mean ± SD of 3 technical replicates. 
 
Having confirmed that the cells indeed expressed luciferase, I hypothesized that the 
subcutaneously injected cells might have disseminated under the skin. This might explain 
the lack of signals during in vivo monitoring. To test this hypothesis, intra-dermal and 
mammary fat pad injections with or without matrigel were carried out to prevent easy 
dissemination of the cells. However, again, in vivo imaging did not detect any signal above 
the background (Figure 37).  
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Figure 37 In vivo imaging of intra-dermal or mammary fat pad injection of bone marrow 
stromal cells Injection of CD45-Ter119-CD31- cells into different parts of the body 1. Intradermal 
injection 2. Intradermal injection with matrigel 3. Mammary fat pad injection 4. Mammary fat pad 
injection with matrigel 5. No injection 
 
After failing to detect a luciferase signal upon different injections, I next hypothesized that 
bone marrow stromal cells might survive better in their physiological microenvironment. 
Therefore, one more test round was performed with intra-tibial injection of cells. It was 
also speculated that presence of signals derived from cancer cells might support the 
maintenance of bone marrow stromal cells. Thus, mouse breast cancer cells, namely 4T1 
cell line were injected into the mammary fat pat of mice and 7 days later, bone marrow 
stromal cells were injected either subcutaneously or into the tibia of the same mice. No 
signal above threshold was detected in any condition (Figure 38).  
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Figure 38 In vivo imaging of intra-tibia or subcutaneous injection of bone marrow stromal 
cells in tumor bearing mice Injection of CD45-Ter119-CD31- cells into mice that are bearing 
tumors formed by orthopedic injection of 4T1 cells 1. 4T1 + CD45-Ter119-CD31- (subcutaneous) 
2. PBS + CD45-Ter119-CD31- (subcutaneous) 3. 4T1 + CD45-Ter119-CD31- (intra-tibia) 4. PBS + 
CD45-Ter119-CD31- (intra-tibia) 
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4. DISCUSSION 
Breast cancer has remained one of the leading causes of cancer related death in women 
worldwide. It is a heterogeneous disease with several molecular subtypes. Identification 
and understanding the underlying biology of these molecular subtypes have resulted in the 
development of targeted therapies against specific molecules including tyrosine kinase 
inhibitors as well as antibodies targeting EGFR, HER2, c-MET and FGFR, inhibitors of 
intracellular signaling pathways targeting PI3K, mTOR and ERK, angiogenesis inhibitors 
and DNA repair interfering agents (Higgins & Baselga, 2011). However, resistance to these 
therapeutic agents and the disease relapse are still some of the major problems.  
The tumor microenvironment has been recognized as a crucial part of tumor progression 
since tumor formation involves the co-evolution of neoplastic cells together with their 
microenvironment including extracellular matrix, tumor vasculature and immune cells 
(Junttila & de Sauvage, 2013). Therefore, understanding the role of the tumor 
microenvironment in cancer formation can reveal new targets for the development of new 
therapies. Since stromal cells in the tumor microenvironment are genetically more stable 
compared to the cancer cells, therapies targeting signaling molecules in the stromal part of 
tumor are likely to be less susceptible to the mechanism of therapeutic resistance (Quail & 
Joyce, 2013).  
Cancer associated fibroblasts (CAF) are a dominant compartment of tumor stroma and they 
are involved in tumor progression by remodeling ECM and by metabolic and immune 
reprogramming of the tumor microenvironment (Kalluri, 2016). In the early tumor 
development, fibroblasts are recruited to the neoplastic legions as part of the host response 
to epithelial tissue injury that might reflect their role in the early antitumor response. This 
situation is similar to wound healing in which activated fibroblasts initiate the repair 
process and control and prevent further tissue damage. Moreover, in the case of wound 
healing, activated fibroblasts are also involved in inducing an intrinsic program that inhibits 
an excessive scarring response that could otherwise further injure the tissue. This program 
is failed to be initiated such as in the case of fibrosis and cancer, diseases associated with 
unabated fibroblast activation resulting in chronic inflammation (LeBleu & Kalluri, 2018). 
Although, the mechanisms behind this unabated activation of fibroblasts remain largely 
unknown, epigenetic reprogramming might be involved in this sustained activated state. It 
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has been shown that hypermethylation of the RASAL1 promoter is associated with unabated 
fibroblast activation and fibrosis in the kidney (Bechtel et al., 2010). In addition it has been 
also demonstrated that CAFs have a global hypomethylation in their genome that might 
result in upregulation of genes associated with the CAF secretome (Jiang et al., 2008). In 
another study in dermal fibroblast it was reported that downregulation of the NOTCH 
protein effector CSL and p53 enables CAF activation and proliferation by overcoming the 
senescence (Procopio et al., 2015).  
CAFs are a very heterogeneous population of cells that might be the outcome of the diverse 
origin of quiescent precursor fibroblasts. It was speculated that depending on their origin, 
activated fibroblasts could have diverse and unique functions in tumor progression (LeBleu 
and Kalluri, 2018). As mentioned in chapter 1.2.3.2., distinct subset of CAFs might have 
either cancer promoting or cancer retraining functions. Although, the early studies using 
CAFs isolated from solid tumors but expanded in vitro, showed mostly tumor promoting 
affects once re-introduced to mice together with cancer cells, it should be noted that tumor 
promoting CAFs, secreting pro-survival factors, might have a selective growth advantage 
over tumor inhibiting CAFs when cultured in vitro (Kalluri, 2016). Therefore, it is crucial 
to track the behavior of distinct CAF populations during different stages of tumor 
development in vivo. However, the lack of in vivo mouse models and imaging tools and the 
lack of specific markers to identify different CAF populations has remained a major 
challenge to study their diverse functions (LeBleu and Kalluri, 2018). Several studies 
targeting and depleting bulk CAF population in the tumor microenvironment for 
therapeutic purposes without having a precise information about subpopulations and their 
role in the tumor progression resulted in unexpected effects on tumor progression possibly 
due to the depletion of tumor restraining CAFs together with the tumor promoting ones 
(see chapter 1.2.3.2.). For this reason, a more effective therapeutic approach to target CAFs 
might be by perturbing the pathways that lead to the activation of fibroblasts instead of 
depleting the whole CAF population. For example, in pancreatic cancer, it has been 
demonstrated that vitamin D receptor ligand calcipotriol converted activated pancreatic 
stellate cells back to their quiescent state and reduced tumor volume when used in 
combination with a chemotherapeutic drug, gemcitabine, by reducing the tumor associated 
inflammation and fibrosis and increasing intra-tumoral gemcitabine (Sherman et al., 2014). 
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These findings emphasize that it is very important to explore the biology behind the 
activation of fibroblasts to unravel the molecular mechanisms behind it. Therefore, one of 
the aims of this PhD project was to understand how the changes in CAFs during the 
activation process are regulated at the molecular level and to identify signaling pathways 
that might be either directly leading this activation or might be involved in it by cross-
talking with signaling pathways that have been already associated with the activation of 
fibroblasts.  
 
4.1. Activation of MSCs upon CM treatment 
In order to study the activation of fibroblasts in vitro, a triple negative breast cancer cell 
line MDA-MB-231 was used to activate bone marrow derived MSCs. MDA-MB-231 cell 
line was chosen due to the previous reports showing its effect on the transformation of 
MSCs to cancer associated fibroblast like cells (Mishra et al., 2008). MSCs were either 
exposed to conditioned media of MDA-MB-231 cells or indirectly co-cultured with them 
in a trans-well format. To assess the activation of MSCs, contractility of the cells was 
measured because increased fibroblast contractility is a major hallmark of CAFs and can 
be monitored by contraction of fibroblast-containing 3D collagen gels (Calvo et al., 2013). 
In addition to the contractility, changes in the expression of activated fibroblast markers 
namely, FAP and αSMA were determined.  While the conditioned media treatment 
activated the MSCs, trans-well co-culture did not have any effect on the activation status 
of MSCs. This might be indicating that MDA-MB-231 secreted factors are potent enough 
to activate MSCs and MDA-MB-231 cells do not need any further stimulation by MSCs to 
secrete those required factors indicating that having no effect on the activation of MSCs 
upon indirect co-culture is due to technical reasons rather than the biological ones. These 
findings firstly demonstrate that factors secreted by MDA-MB-231 are sufficient to 
activate MSCs and that no feedback from MSCs to the tumor cells is necessary to stimulate 
secretion of those factors. Secondly, the experimental setup was likely responsible for the 
lack of MSC-induction in the trans-well assay, probably due to the different concentrations 
of factors. One of these might be having less concentrated conditioned media of MDA-
MB-231 in the indirect co-culture settings due to having less starting cell number. 
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Conditioned media treatment was done for 7 or 14 days to be able to monitor possible 
gradual activation of MSCs. Indeed, flow cytometry analysis revealed that while FAP is 
upregulated at protein level even after 7 days of treatment, αSMA was upregulated only 
after 14 days. This might reflect that although some signaling pathways can be immediately 
activated by conditioned media treatment, activation of MSCs is a gradual process that 
requires continuous exposure to the stimuli.  
Another very important point to discuss is the baseline activation of MSCs. Both collagen 
gel contraction assay and flow cytometry analysis of activated fibroblast markers revealed 
that MSCs are already activated to a certain extent in the normal culture conditions. This 
observation is in line with several studies that showed that artificial culturing conditions 
such as plastic cell culture dishes or presence of fetal bovine serum in culturing media is 
enough to activate the cells (Pal & Das, 2017).  Hence, this baseline activation of MSCs 
reduced the dynamic range of the assay when measuring the effect of conditioned media 
treatment on the activation of MSCs. I could still identify major effects, validating my main 
focus on finding changes induced upon treatment with conditioned media. These included 
a upregulation of several cytokines, which have been shown to be secreted by CAFs, upon 
conditioned media treatment showing that although MSCs have already a baseline 
activation, conditioned media treatment still has an immense effect on MSCs.  
 
4.2. Effect of activated MSCs on cancer cells 
Since CAFs have been associated with almost all aspects of tumor progression in breast 
cancer (Qiao et al., 2016), another way to assess the activation of MSCs could be 
determining their effect on the phenotype of breast cancer cells. To this end, MSCs treated 
with media or conditioned media were directly co-cultured with different breast cancer cell 
lines and their proliferation was assessed. While, no change was observed in the growth of 
MDA-MB-231 and HCC1943 cells, the presence of MSCs had a positive effect on the 
growth of T47D, MCF7 and HS578T cell lines. However, the only difference between 
media or conditioned media treated MSCs was observed in HS578T cells. These 
differences might be explained by the fact that these cell lines are models of different breast 
cancer subtypes. HS578T cells are the only cells in this panel belonging to the 
mesenchymal sub-subtype of triple negative breast cancer. Therefore, this experiment 
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could be repeated using another mesenchymal cell line such as BT549 to test this 
hypothesis.  
In addition to the breast cancer cell growth, other important phenotypes that can be affected 
by activated fibroblasts are migration and invasion ability of the breast cancer cell lines 
because one of the most important characteristics of CAFs is their supporting role in cancer 
metastasis (Gaggioli et al., 2007; Scherz-Shouval et al., 2014). When MDA-MB-231 cells 
were exposed to the conditioned media of activated MSCs, there was no difference in the 
invasion or migration ability compared to media-treated MDA-MB-231 cells (data not 
shown). This could be because of high baseline invasion and migration ability of this cells. 
To assess whether conditioned media-treated activated MSCs have a role in cancer cell 
motility, less motile luminal cell lines such as T47D and MCF7 could be also tested. It is 
important to note that CAFs in the tumor microenvironment affect tumor progression not 
only by interacting with cancer cells but also with immune cells and endothelial cells. 
Therefore, in addition to determining the impact of activated MSCs on cancer cell 
phenotype, effect of MSCs on immune cells could be also analyzed.  
 
4.3. Methylation, gene expression and secretome analysis of activated MSC 
Since it has been reported that epigenetic reprogramming might be involved in the 
activation of fibroblasts (Bechtel et al., 2010; Jiang et al., 2008), the changes in DNA 
methylation pattern of MSCs upon conditioned media treatment were analyzed at a global 
scale. Even with 14 days of CM treatment, out of 8.5x105 tested probes, only up to 2% of 
them were differentially methylated. This might be due to short duration of conditioned 
media treatment. DNA methylation changes are introduced in the genome by successive 
cell divisions, however during the conditioned media treatment MSCs were passaged only 
once which might be a limiting factor for the detection of possibly induced DNA 
methylation changes. 
In addition to the methylation analysis, expression analysis by RNA sequencing was 
performed. Pathway enrichment analysis was done using RNA sequencing data and it 
identified TNFα signaling, chemokine signaling pathways, cytokine-cytokine receptor 
interaction and NFB signaling pathway as top regulated pathways both after 7 and 14 
days of conditioned media treatment. This indicates an upregulated proinflammatory gene 
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signature that is in line with the upregulation of various cytokines. One of the hallmarks of 
cancer is the tumor promoting inflammation (Hanahan & Weinberg, 2011). Inflammation 
is associated with activation of the canonical NF-κB pathway (Barnes & Karin, 1997). 
Genes of many pro-inflammatory cytokines including but not limited to TNFα, IL-1, IL-6 
and IL-8 have been shown to have NF-κB binding sites in their respective promoter regions 
and activation of NF-κB pathway has been reported to be crucial for their expression 
(Bonizzi & Karin, 2004). These cytokines can promote tumor progression by inducing 
angiogenesis, cancer cell proliferation and metastasis and they also maintain the 
inflammatory tumor microenvironment (Grivennikov & Karin, 2011). CAFs have been 
several times implicated as novel mediators of tumor promoting inflammation (Servais & 
Erez, 2013). Moreover, it is has been demonstrated that inflammatory features associated 
with CAFs are dependent on NF-κB signaling (Erez et al., 2010). Therefore, my 
observation of upregulation of inflammatory pathways upon conditioned media treatment 
is in line with the inflammatory characteristics of CAFs.  
Due to the capability of CAFs to secrete vast number of soluble factors and extracellular 
matrix components, secretome analysis was done using mass spectrometry, in 
collaboration with Prof. J. Krijgsveld, to identify differentially secreted proteins upon 
conditioned media treatment. Several proteins identified as being secreted more upon 
activation of MSCs had previously been reported as CAF secreted factors such as IL6 (Kato 
et al., 2018), MMP1 (Cui et al., 2018), MMP13 (Folgueira et al., 2013) and GAS6 (Kanzaki 
et al., 2017). Since I wanted to study new factors that have a role in the activation of 
fibroblasts, I followed up several upregulated target genes. Several like CHI3L1, CHI3L2, 
GREM1 and TGM2, did not show any effect on the activation status of MSCs upon their 
knock-down by siRNAs (data not shown). The reason behind this could be their 
upregulation as a result of activation of MSCs without having a role as the driver of this 
activation. Moreover, they might be upregulated as a response to a factor in the conditioned 
media without being involved in the activation of MSCs. Another target, STC1, was 
selected because it was among the top differentially secreted proteins in mass spectrometry 
analysis and was also detected to be upregulated in expression analysis. 
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4.4. Stanniocalcin 1  
Stanniocalcin (STC) was first discovered in bony fish as a glycosylated peptide produced 
by endocrine glands in the kidney (Wagner et al., 1986). The protein is expressed and 
secreted as a response to increased calcium concentration in water (Ellis & Wagner, 1995) 
and inhibits calcium uptake via inhibition of epithelial calcium channel mRNA expression 
(Tseng et al., 2009). In mammals, two members of the STC family have been identified 
(A. C. Chang et al., 1995; A. C. Chang & Reddel, 1998). STC1 has 61% sequence identity 
with fish STC and STC1 has 30% sequence identity with STC2 (Yeung et al., 2012).  
In the first in vivo study in mice that explored the role of STC1 in bone formation, when 
SCT1 was expressed under the control of a muscle specific promoter, dwarf morphology 
with decreased bone formation was observed in mice (Filvaroff et al., 2002). Although 
similar to its fish homolog, recombinant human STC1 has inhibitory effects on calcium 
uptake in human cells (Zhang et al., 2000; Sheikh-Hamad et al., 2003),  STC1 knock-out 
mice (-/-) did not have any phenotype (A. C.-M. Chang et al., 2005) indicating that 
mammalian STC1 is not involved in calcium homeostasis and that the fish and mammalian 
STC proteins are not functional orthologs.  
STC1 is expressed in wide variety of tissues including heart, lung, kidney, femur and ovary  
(A. C. Chang et al., 1995) and has been reported to be involved in diverse biological 
processes such as osteogenesis (Yoshiko et al., 2002) , inflammation (Kanellis et al., 2004) 
and cellular metabolism (McCudden et al., 2002). STC1 was demonstrated to be 
upregulated as a response to hypoxia (Zhang et al., 2000). Moreover, STC1 secreted by 
MSCs has been shown to have inhibitory effects on apoptosis that is induced by hypoxia 
(Block et al., 2009) or by reactive oxygen species (Ohkouchi et al., 2012). This observation 
might be explained by its localization in mitochondria upon internalization where it induces 
mitochondrial uncoupling proteins (UCPs) that in turn reduce the formation of reactive 
oxygen species (Y. Wang et al., 2009).  
STC1 has been reported to be differentially expressed in paired human tumor and normal 
tissues with an upregulation in several types of cancer including colorectal cancers, 
hepatocellular carcinomas, non-small cell lung cancer, ovarian cancer, leukemia, and breast 
carcinoma (Chu et al., 2015) and to be associated with tumor progression in renal (Ma et 
al., 2015) breast (Welcsh et al., 2002) and ovarian cancers (Liu et al., 2010). It has been 
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shown to be involved in tumor growth, epithelial-mesenchymal transition and apoptosis 
(Chu et al., 2015).  
There are also several studies that have reported STC1 as a CAF-secreted factor and have 
associated the protein with metastasis in colorectal carcinoma (Peña et al., 2013) and with 
therapy resistance in breast cancer (Roswall et al., 2018). However, the molecular 
mechanisms behind the roles of CAF secreted STC1 have not been elucidated.  
 
4.5. Role of STC1 in the activation of MSCs and CAFs 
In order to investigate the role of STC1 on activation of MSCs upon conditioned media 
treatment, STC1 was down-regulated in MSCs using siRNAs before treatment with 
conditioned media. It was observed that STC knock-down not only decreased the 
contraction ability of MSCs but also reversed the upregulation of FAP in MSCs treated 
with the conditioned media for 7 days as well as the upregulation of SMA in MSCs treated 
with the conditioned media for 7 or 14 days. Moreover, STC1 knock-down also 
downregulated baseline SMA expression. It has been reported that expression of SMA 
is correlated with the contractility of fibroblasts (Shinde et al., 2017; B Hinz et al., 2001) 
however, there are also other factors involved in the contraction of these cells such as 
activation of transcriptional regulator YAP (Calvo et al., 2013). Therefore, STC1 could 
inhibit the contraction of activated MSCs, however, that this might not be a direct effect of 
SMA downregulation.  
To test the effect of STC1 know-down on already activated patient-derived CAFs, baseline 
STC1 expression was determined in different primary CAFs having been isolated from 
different patient tumors. Two CAF lines, namely CAF1 and CAF2 having highest 
expression of STC1, were chosen for further experiments. While STC1 knock-down in 
these cells reduced the contractility of the CAF1 cell, it did not have any effect of CAF2 
cells. In line with this observation, STC1 down-regulation resulted in downregulation of 
SMA in CAF1 cells but did not cause any change in CAF2 cells. This could be due to 
lower baseline levels of SMA in and lower contractility of CAF2 compared to CAF1 
cells. These results suggest that the activation level of CAFs is important to see an effect 
of STC1 knock-down. Furthermore, it should be noticed that CAF1 cells express higher 
levels of STC1 compared to CAF2 cells which could further support a role of STC1 in the 
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activation of fibroblasts. However, to test this hypothesis, more CAFs from different 
tumors should be examined.  
Using CAF1 cells, the effect of STC1 on another characteristic of activated fibroblasts was 
tested. STC1 knock-down decreased the number of invading and migrating CAFs. In 
addition to their impact on cancer cell migration and invasion, migration and invasion are 
also important features for CAFs. It has been recently shown that  CAFs exert a physical 
force via CAF-cancer cell adhesion and promote a cooperative collective invasion or 
migration of CAFs and cancer cells (Labernadie et al., 2017).  
All in all, it could be summarized that due to its effect on contractility, SMA expression, 
migration and invasion in CAFs, STC1 could have a role in the activation of fibroblasts. 
This presumed role of STC1 in the activation of fibroblasts does not fit with the results 
from a previous study where the inhibitory effects of recombinant STC1 in bleomycin-
induced idiopathic pulmonary fibrosis by decreasing collagen deposition and intracellular 
ROS amounts was shown (Ono et al., 2015). In the same study, it was demonstrated that 
STC1 expression can be induced by TGF in MSCs and when MSCs injected in mice, they 
have the same effect on fibrosis as recombinant STC1 does. While the observed inhibitory 
effect on fibrosis might imply an inhibitory role of STC1 on the activation of fibroblasts, 
this study does not mention the effects of STC1 in the activated fibroblasts that are already 
in the fibrotic area. Therefore, the difference in the experimental setup and lack of evidence 
of direct effects of STC1 on the cells within fibrotic areas suggests that further studies need 
to be carried out to understand how STC1 is involved in the activation of fibroblasts.  
 
4.6. Regulation of STC1 by NF-κB signaling 
STC1 upregulation in MSCs treated with conditioned media was rescued almost 70% when 
two transcription factors of NF-κB signaling, RELA and RELB, were down-regulated 
using siRNA. This observation is in line with the study in which it has been shown that the 
STC1 promoter has two putative binding sites for RELA and the transcriptional regulation 
of STC1 by RELA was confirmed by chromatin immunoprecipitation (Law et al., 2008). 
Since STC1 upregulation by conditioned media treatment was indeed rescued with the 
downregulation of both RELA and RELB, it can be speculated that conditioned media 
treatment is inducing both canonical and non-canonical NF-κB signaling since RELA and 
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RELB take part in either one respectively (Shao-Cong Sun, 2018). These two pathways 
can be induced by the same or different ligands; therefore, it is hard to speculate about the 
factor(s) in the conditioned media inducing NF-κB signaling. Moreover, although it has 
been shown that RELA can directly bind to the promoter of STC1, upregulation via 
conditioned media might be also induced by NF-κB signaling indirectly as a result of the 
activation of the pathway. To address this question, binding of RELA or RELB to the STC1 
promoter with or without conditioned media treatment should could be determined by 
chromatin immunoprecipitation assay. If there is no direct binding, different transcription 
factors that might be activated by NF-κB signaling with a potential to bind to the STC1 
promoter could be examined. Moreover, rescue of STC1 upregulation via RELA or RELB 
knock-down was not complete. This might be because of either that STC1 upregulation is 
controlled also by other means or knock-down level for RELA and RELB is not efficient 
enough to result in a full rescue. However, it can be still concluded that STC1 upregulation 
upon conditioned media treatment is an outcome of a proinflammatory programming that 
results in changes of inflammatory pathways of activated MSCs. 
 
4.7. Pathways regulated by STC1 knock-down 
In order to identify the molecular mechanism by which STC1 plays a role in the activation 
of fibroblasts, the pathways that are differentially activated upon STC1 knock-down were 
determined by RPPA. There were indeed changes in the expression of proteins of the Notch 
and Wnt signaling pathways. Two receptors of Notch signaling, NOTCH3 and NOTCH4 
were found to be down-regulated. Notch signaling is involved in diverse biological process 
from embryonic development and stem cell regulation to heart morphogenesis and cancer. 
Upon ligand binding, receptors of the NOTCH family undergo proteolytic cleavage, 
releasing Notch intracellular domains of the receptors (NICD) which enter the nucleus and 
stimulate the transcription of target genes (Bray, 2016). Several studies have mentioning 
the involvement of NOTCH signaling in the activation of fibroblasts: it has been 
demonstrated that stimulation of dermal fibroblasts with recombinant Jag-1, a Notch 
ligand, results in gaining myofibroblast like phenotype and increased collagen release 
(Dees et al., 2011). In another study in oral squamous cell carcinoma, NOTCH3 expression 
in CAFs has been associated with poor prognosis (Kayamori et al., 2016). Therefore, it can 
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be speculated that STC1 knock-down by down-regulating Notch signaling can attenuate 
fibroblast activation. Interestingly, there is a publication demonstrating STC1 as a non-
canonical NOTCH ligand and showing its interaction with extracellular domain of 
NOTCH1 thereby regulating stemness in glioblastoma (Li et al., 2018). Therefore, Notch 
signaling could be a possible target to explain the role of STC1 in fibroblast activation. In 
order to study this, Notch pathway inhibitors in the context of STC1 overexpression could 
be tested. 
Another protein that was determined to be down-regulated by STC1 knock-down was β-
catenin. β-catenin is the central protein in Wnt signaling pathway. Wnt signaling has been 
already associated with the activation of fibroblasts (see chapter 1.2.2.) mostly by cross-
talk with the TGF pathway. STC1 knock-down also resulted in a decreased in the 
phosphorylated levels of SMAD3 protein. Therefore, it can be hypothesized that STC1 
knock-down can cause inhibition of fibroblast activation by downregulating β-catenin 
thereby inhibiting TGF signaling. To test this hypothesis, effect of STC1 overexpression 
on the activity of Wnt signaling pathway could be analyzed. The putative involvement of 
STC1 in the Wnt pathway has recently been suggested as STC1 seems to be a Wnt3a target 
gene in the context of osteogenesis (Sebastian et al., 2017).  
 
4.8. STC1 expression in breast cancer patient datasets 
Possible role of STC1 in the activation of fibroblasts opens up several research questions 
about localization of its expression in the tumor microenvironment. Although, STC1 has 
been several times shown to be a CAF secreted factor in vivo, most of the breast cancer cell 
lines also express it to some extent. Therefore, it is important to understand which 
compartment of the tumor expresses STC1. For this, breast cancer patient data sets which 
have separate information of stroma and epithelium of tumor samples were analyzed. 
Despite of having significantly more STC1 expression in the tumor stroma of DCIS 
compared to the epithelium of DCIS in one data set (GSE14548), in another one this 
difference was not observed (GSE35019). Moreover, when STC1 expression was 
compared between normal stroma and tumor stroma, although a significant difference was 
detected in one data set (GSE9014), it was not the case in another one (GSE5847). These 
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differences might be the result of small cohorts of these data sets and to have more concrete 
data, more patient data sets with bigger cohorts could be analyzed.  
 
4.9. In vivo tracking of MSCs recruited from bone marrow to the tumor 
microenvironment 
When this project started in 2015, there was no in vivo proof of recruitment of bone marrow 
stromal cells from bone marrow to the breast cancer microenvironment. Bone marrow 
stromal cells had been shown to be a heterogeneous group of cells. Therefore, I 
hypothesized that if bone marrow stromal cells are indeed migrating to the tumor 
microenvironment in breast cancer, different populations might have different behavior in 
this migration process. In order to address this question, bone marrow cells injected into 
tibia of mice were attempted to be monitored using their luciferase expression. However, 
the cells were never able to being detect either in tibia or in anywhere else in the mice. 
There could be several reasons for this. First of all, although it was shown that bone marrow 
stromal cells were expressing luciferase upon isolation, once they were injected into mice, 
they might have stopped expressing luciferase due to several reasons such as inactivation 
of the genomic locus of luciferase gene. Also, luciferase expressing cells might have 
generated an immune response and have been cleared up by immune cells. Although there 
are publications showing engraftment of stromal cells when injected directly in the bone 
marrow, due to several possible factors, engraftment might have failed. A better strategy 
for this could be performing a bone marrow transplantation instead of injecting bone 
marrow stromal cells alone that might facilitate their survival. Indeed, a recent study using 
bone marrow transplantation strategy has demonstrated bone marrow stromal cells to be a 
substantial source for CAFs in the breast cancer microenvironment (Yaz et al., 2018), thus 
validating my original concept. 
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5. CONCLUSIONS AND OUTLOOK 
In conclusion, I have shown that bone marrow derived MSCs can be activated by treating 
them with conditioned media of MDA-MB-231 cells. Conditioned media treatment 
induced a transcriptional reprogramming in which inflammation related genes were 
upregulated. STC1 was identified as an upregulated gene upon activation of MSCs and this 
upregulation was controlled by two transcription factors of NF-κB signaling, RELA and 
RELB indicating that it might be also the result of the inflammatory response. The role of 
STC1 on the activation of MSCs as well as patient derived CAFs was demonstrated by 
down-regulating its expression. Furthermore, this down-regulation resulted in a decreased 
in the expression of several proteins such as NOTCH3, NOTCH4 and β-catenin suggesting 
possible mechanisms by which STC1 regulates the activation of fibroblasts.  
Activation of MSCs upon conditioned media treatment was assessed with increased 
contractility and increased expression of two CAF markers, FAP and SMA. To 
demonstrate that the activation of MSCs has an effect on tumor progression, the influence 
of activated MSCs on cancer cells and/or immune cells will be investigated in vitro.  
There is evidence that STC1 upregulation in activated MSCs upon conditioned media 
treatment is regulated by RELA and RELB. To confirm NF-κB pathway is directly 
responsible for this upregulation, direct binding of RELA and RELB in the promoter region 
of STC1 will be explored. 
While the regulatory role of STC1 in the activation of fibroblasts was demonstrated, the 
molecular mechanism behind this is not clear. To address this, the involvement of Notch 
and Wnt signaling in the activation of fibroblasts as well as their interaction with STC1 
will be studied.  
Gaining further insights into the activation of fibroblasts could offer a deeper understanding 
of their origin, plasticity and function in the tumor microenvironment and could provide 
new therapeutic targets. Investigating the role of STC1 in the unabated activation of CAFs 
will enable a deeper understanding of the tumor microenvironment and its role in the tumor 
progression and aid in the development of better therapeutic strategies. 
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ABBREVIATIONS 
AHA L-Azidohomoalanine 
ATP Adenosine triphosphate 
BM Bone marrow 
BMPR Bone morphogenic protein receptor 
BRCA Breast Cancer 
CAF Cancer associated fibroblast 
CBP CREB binding protein 
CC Co-culture 
CCL C-C Motif Chemokine Ligand  
CCND1 Cyclin D1 
CM Conditioned media 
CSF1 Colony Stimulating Factor 1 
CTGF Connective tissue growth factor 
CXCL Chemokine (C–X–C motif) ligand 
CO2 Carbon dioxide 
cDNA Complementary deoxyribonucleic acid 
D Donor 
DNA Deoxyribonucleic acid 
DEG Differentially expressed genes 
DMP Differentially methylated probes 
DMSO Dimethyl sulfoxide 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ELISA Enzymed-linked immunosorbent assay 
EMT Epithelial-mesenchymal transition 
ER Estrogen receptor 
ERBB2 Erb-B2 Receptor Tyrosine Kinase 2 
ESR1 Estrogen Receptor 1 
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FAP Fibroblast activation protein alpha 
FBS Fetal Bovine Serum 
FC Fold change 
FSP1 Fibroblast specific protein 1 
FGF Fibroblast growth factor  
GTP Guanosine triphosphate 
HER2 Human Epidermal Growth Factor Receptor 2 
HSC Hematopoietic Stem Cells 
HIF1α Hypoxia inducible factor 1α 
IL Interleukin 
IκB Inhibitor of kappa B 
LOX Lysyl Oxidase 
M Media 
MAC-1 Macrophage 1 Antigen 
MC Mono-culture 
MPP Matrix metalloproteinases 
MAPK Mitogen-Activated Protein Kinase 
MPER Mammalian Protein Extraction Reagent 
mRNA Messenger ribonucleic acid 
MSC Mesenchymal stromal cells 
mTOR Mechanistic Target of Rapamycin Kinase 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NaF Sodium Fluoride 
NEAA Non-essential amino acids 
TP53 Tumor protein 53 
PARP Poly (ADP-Ribose) Polymerase 
PBS Phosphate buffered saline 
PDGF Platelet derived growth factor 
PDGFR Platelet derived growth factor receptor 
PD-1 Programmed cell death protein 
PD-L Programmed cell death protein ligand 
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PenStep Penicillin/Streptomycin 
PGE Prostaglandin E synthase 
PI3K Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 
PR Progesterone receptor 
PTEN Phosphatase and Tensin Homolog 
PUM1 Pumilio RNA Binding Family Member 1 
qRT-PCR Quantitative reverse transcriptase polymerase chain reaction 
RNA Ribonucleic acid 
RNAi Ribonucleic acid interference 
ROS Reactive oxygen species 
RPPA Reverse phase protein array 
RT Room temperature 
RTCA Real time cell analyzer 
SD Standard deviation 
SILAC Stable isotope-labeled amino acids 
siRNA Small interfering ribonucleic acid 
TBST Tris buffered saline with Tween 20 
SBE Smad binding elements 
STC1 Stanniocalcin 1 
TAM Tumor associated macrophage 
TCGA The Cancer Genome Atlas 
TGF Transforming growth factor beta 
TGFR Transforming growth factor beta receptor 
TIL Tumor infiltrating lymphocytes 
TIMP Tissue inhibitor of metalloproteinase  
TNBC Triple negative breast cancer 
TNFα Tumor Necrosis Factor 
Tregs Regulatory T cells 
TW Trans-well 
VEGF Vascular endothelial growth factor 
SMA alpha smooth muscle actin 
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